<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Croat Med J</journal-id><journal-id journal-id-type="iso-abbrev">Croat Med J</journal-id><journal-id journal-id-type="publisher-id">CMJ</journal-id><journal-title-group><journal-title>Croatian Medical Journal</journal-title></journal-title-group><issn pub-type="ppub">0353-9504</issn><issn pub-type="epub">1332-8166</issn><publisher><publisher-name>Croatian Medical Schools</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40343433</article-id><article-id pub-id-type="pmc">PMC12093125</article-id><article-id pub-id-type="publisher-id">CroatMedJ_66_0100</article-id><article-id pub-id-type="doi">10.3325/cmj.2025.66.100</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Disease characteristics and outcomes of Croatian pediatric patients with acute lymphoblastic leukemia: pretreatment immunophenotypic predictors of high bone marrow minimal residual disease on day 15 of treatment</article-title><alt-title alt-title-type="running-head">Dubrav&#x0010d;i&#x00107; et al: Disease characteristics and outcomes of Croatian pediatric patients with acute lymphoblastic leukemia</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dubrav&#x0010d;i&#x00107;</surname><given-names>Klara</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tr&#x0010d;i&#x00107;</surname><given-names>Ru&#x0017e;ica Lasan</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bili&#x00107;</surname><given-names>Ernest</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Konja</surname><given-names>Josip</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Raji&#x00107;</surname><given-names>Ljubica</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Femeni&#x00107;</surname><given-names>Ranka</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff17" ref-type="aff">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pavlovi&#x00107;</surname><given-names>Maja</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kuve&#x0017e;di&#x00107;</surname><given-names>Koraljka Gjadrov</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ries</surname><given-names>Sun&#x0010d;ica</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Su&#x0010d;i&#x00107;</surname><given-names>Mirna</given-names></name><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>&#x00160;imi&#x00107;</surname><given-names>Ivana Frani&#x00107;</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zadro</surname><given-names>Renata</given-names></name><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Antolic</surname><given-names>Margareta Radi&#x00107;</given-names></name><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Horvat</surname><given-names>Ivana</given-names></name><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jakovljevi&#x00107;</surname><given-names>Gordana</given-names></name><xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Roganovi&#x00107;</surname><given-names>Jelena</given-names></name><xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref><xref rid="aff11" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>&#x0010c;uli&#x00107;</surname><given-names>Sr&#x00111;ana</given-names></name><xref rid="aff12" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kulji&#x00161;</surname><given-names>Dubravka</given-names></name><xref rid="aff12" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Armanda</surname><given-names>Vi&#x00161;nja</given-names></name><xref rid="aff12" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tudor</surname><given-names>Karolina Mali&#x00107;</given-names></name><xref rid="aff12" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>&#x00160;erifi</surname><given-names>Senada</given-names></name><xref rid="aff13" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lozi&#x00107;</surname><given-names>Bernarda</given-names></name><xref rid="aff12" ref-type="aff">
<sup>12</sup>
</xref><xref rid="aff14" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Batini&#x00107;</surname><given-names>Drago</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff15" ref-type="aff">
<sup>15</sup>
</xref></contrib><aff id="aff1"><label>1</label>Division of Flow Cytometry, Department of Laboratory Diagnostics, Children's Hospital Zagreb, Zagreb, Croatia</aff><aff id="aff2"><label>2</label>Division for Cytogenetics, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia</aff><aff id="aff3"><label>3</label>Department of Pediatric Hematology and Oncology, University Hospital Centre Zagreb, Zagreb, Croatia</aff><aff id="aff4"><label>4</label>School of Medicine, University of Zagreb, Zagreb, Croatia</aff><aff id="aff5"><label>5</label>Department of Pathology and Cytology, University Hospital Centre Zagreb, Zagreb, Croatia</aff><aff id="aff6"><label>6</label>Division of Cytology, Department of Pathology and Cytology, Sveti Duh University Hospital, Zagreb, Croatia</aff><aff id="aff7"><label>7</label>Department of Laboratory Diagnostics, St Catherine Specialty Hospital, Zagreb, Croatia</aff><aff id="aff8"><label>8</label>Division of Laboratory Hematology and Coagulation, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia</aff><aff id="aff9"><label>9</label>Medical- biochemical Laboratory, Polyclinic Analiza, Vara&#x0017e;din, Croatia</aff><aff id="aff10"><label>10</label>Department of Oncology and Hematology, Children's Hospital Zagreb, Zagreb, Croatia</aff><aff id="aff11"><label>11</label>Faculty of Biotechnology and Drug Development, University of Rijeka, Rijeka, Croatia</aff><aff id="aff12"><label>12</label>Department of Pediatrics, University Hospital of Split, Split, Croatia</aff><aff id="aff13"><label>13</label>Department of Pediatric Hematology and Oncology, Department of Pediatrics, University Hospital Center Rijeka, Rijeka, Croatia</aff><aff id="aff14"><label>14</label>University of Split School of Medicine, Split, Croatia</aff><aff id="aff15"><label>15</label>Division of Laboratory Immunology, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia</aff><aff id="aff16"><label>15</label>School of Medicine, University of Zagreb, Zagreb, Croatia</aff><aff id="aff17"><label>*</label>The author died on November 9, 2024, prior to article publication.</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to:&#x02028;Klara Dubrav&#x0010d;i&#x00107;&#x02028;Division of Flow Cytometry&#x02028;Department of Laboratory Diagnostics&#x02028;Children's Hospital Zagreb&#x02028;Vjekoslava Klai&#x00107;a 16&#x02028;10000 Zagreb, Croatia&#x02028;<italic><email xlink:href="klara.dubravcic@gmail.com">klara.dubravcic@gmail.com</email></italic></corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2025</year></pub-date><volume>66</volume><issue>2</issue><fpage>100</fpage><lpage>114</lpage><history><date date-type="received"><day>12</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>11</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 by the Croatian Medical Journal. All rights reserved.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/2.5/</ali:license_ref><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Aim</title><p>To assess the clinical-biological characteristics and outcomes of Croatian pediatric patients with acute lymphoblastic leukemia (ALL). A secondary aim was to evaluate the predictive value of pretreatment leukemia-associated immunophenotypes (LAIPs) for poor early response to induction therapy defined as &#x02265;10% day 15 bone marrow flow cytometry minimal residual disease (FCM-MRD).</p></sec><sec><title>Methods</title><p>This retrospective cohort study reviewed the medical data of 393 consecutive pediatric ALL patients diagnosed and treated from February 2003 to April 2017 at four Croatian pediatric hemato-oncology centers. FCM data of 379 non-infant patients enrolled in two consecutive intercontinental trials, ALL IC-BFM 2002 (NCT00764907) and ALL IC-BFM 2009 (EudraCT 2010-019722-13), were analyzed to evaluate the association between LAIPs at diagnosis and day 15 FCM-MRD&#x02265;10% using univariate and multivariate logistic regression.</p></sec><sec><title>Results</title><p>The median age at diagnosis was 5.2 years, with a predominance (83%) of B-cell precursor (BCP) ALL, and high hyperdiploidy (25.1%) and <italic>ETV6::RUNX1</italic> (18.7%) as the most common genetic abnormalities. The protocols did not significantly differ in 5-year event-free survival (82.1% vs 81.7%), overall survival (88% vs 85%), and cumulative incidence of relapse (12.3% vs 10%). FCM-MRD&#x02265;10% on day 15 was identified in 22.1% of patients and was predicted by white blood cell (WBC) count &#x02265;20&#x02009;&#x000d7;&#x02009;10<sup>9</sup>/L (<italic>P</italic>&#x02009;=&#x02009;0.011) and strong expression of CD34 (<italic>P</italic>&#x02009;=&#x02009;0.032) and CD13 (<italic>P</italic>&#x02009;=&#x02009;0.001) at diagnosis.</p></sec><sec><title>Conclusion</title><p>The characteristics and survival rates of Croatian pediatric ALL patients aligned with ALL IC-BFM data. WBC&#x02265;20&#x02009;&#x000d7;&#x02009;10<sup>9</sup>/L, CD34<sup>strong</sup>, and CD13<sup>strong</sup> independently predicted poor early response in BCP-ALL, suggesting a potential prognostic value of LAIPs at diagnosis.</p></sec></abstract></article-meta></front><body><p>Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, affecting children of all ages, with a peak incidence between two and five years of age and a slightly higher prevalence in boys (<xref rid="R1" ref-type="bibr">1</xref>). ALL is a heterogeneous disease originating from B- or T-cell precursors. Consequently, the contemporary multidisciplinary approach to leukemia diagnosis and classification by the World Health Organization (WHO) incorporates immunophenotype (lineage) and genetic abnormalities to define clinically, biologically, and therapeutically relevant disease entities (<xref rid="R2" ref-type="bibr">2</xref>).</p><p>The survival of children with ALL has improved dramatically, which represents one of the greatest accomplishments in oncology. This improvement is attributed to the progressive development of intensive multiagent chemotherapy protocols based on the results of international cooperative group trials and the introduction of risk-adapted therapy using pretreatment clinical-biological prognostic features and early treatment response assessment for more individually tailored therapy intensity (<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R3" ref-type="bibr">3</xref>).</p><p>Flow cytometry (FCM) is a highly reliable method for assessing leukemic lymphoblast clearance. Patients with high minimal residual disease (FCM-MRD)&#x02265;10% in bone marrow on day 15 during induction therapy fared particularly poorly, independent of initial clinical and biological features (<xref rid="R4" ref-type="bibr">4</xref>). A more sensitive real-time quantitative polymerase chain reaction (RQ-PCR) is better suited for assessing the quality of remission at later time points (<xref rid="R4" ref-type="bibr">4</xref>-<xref rid="R7" ref-type="bibr">7</xref>). Many countries within the International Berlin&#x02013;Frankfurt&#x02013;M&#x000fc;nster Study Group (I-BFM-SG) do not perform PCR-MRD. National groups that joined the intercontinental consortium (ALL IC) agreed to apply only FCM-MRD on day 15 in the randomized clinical trial ALL IC-BFM 2009 in addition to the previous ALL IC-BFM 2002 risk stratification scheme (<xref rid="R8" ref-type="bibr">8</xref>&#x02013;<xref rid="R11" ref-type="bibr">11</xref>).</p><p>MRD is currently the most powerful independent prognostic factor in childhood ALL as a measure of drug resistance <italic>in vivo</italic> and, therefore, a surrogate marker of an individual response (<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R13" ref-type="bibr">13</xref>). For that reason, MRD as a surrogate endpoint for the early evaluation of the treatment efficacy can rapidly resolve the problem of stratifying patients with rare or recently identified genetic and immunophenotypic aberrations, revealing their prognosis (<xref rid="R14" ref-type="bibr">14</xref>).</p><p>Blasts in ALL show immunophenotypic aberrations, ie, leukemia-associated immunophenotypes (LAIPs), even within the subcategories defined by the European Group for the Immunological Characterization of Leukemias (EGIL) classification (<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref>). Although EGIL classification is not of prognostic value, LAIP characterization at diagnosis has reestablished its prognostic significance, not only for FCM-MRD but also for defining new high-risk leukemia subtypes characterized by specific immunophenotypes with poor early response and high MRD levels during therapy (<xref rid="R17" ref-type="bibr">17</xref>-<xref rid="R25" ref-type="bibr">25</xref>). To date, no studies have explored the immunophenotypic predictors of poor early treatment response, defined as FCM-MRD&#x02265;10% on day 15. Furthermore, our study provides the first overview of the characteristics and treatment outcomes of Croatian pediatric ALL patients.</p><p>The aim of this retrospective cohort study was to establish the clinical-biological characteristics and survival outcomes of Croatian pediatric ALL patients treated according to protocols ALL IC-BFM 2002 (NCT00764907) and ALL IC-BFM 2009 (EudraCT 2010-019722-13). Additionally, we characterized LAIPs at diagnosis and evaluated their association with high FCM-MRD levels in bone marrow on day 15 of induction therapy to assess their predictive potential for poor response.</p><sec sec-type="methods"><title>PATIENTS AND METHODS</title><sec><title>Patients and treatment protocols</title><p>We retrospectively reviewed data from 393 consecutive, unselected patients aged &#x02264;18 years with <italic>de novo</italic> ALL diagnosed between February 2003 and April 2017 at four Croatian pediatric hemato-oncology centers (University Hospital Centre Zagreb, Children's Hospital Zagreb, University Hospital of Split, University Hospital Center Rijeka). Two patients continued treatment abroad, and 12 were infants enrolled in the INTERFANT 99/06 protocols. The remaining 379 patients aged &#x0003e;1 year were treated according to one of two subsequent protocols: ALL IC-BFM 2002 (n&#x02009;=&#x02009;196; 49.9%) or ALL IC-BFM 2009 (n&#x02009;=&#x02009;183; 46.6%), depending on the time of diagnosis (<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R11" ref-type="bibr">11</xref>). Details of diagnostics and risk stratification are given in Supplemental Methods<xref rid="S6" ref-type="supplementary-material">(Supplemental Methods)</xref>. Written informed consent was obtained from the parents or legal guardians of the participants before the initiation of treatment. The study was approved by the Ethics Committee of the University Hospital Center Zagreb and the Ethics Committee of the Faculty of Pharmacy and Biochemistry, University of Zagreb.</p></sec><sec><title>Immunophenotypic analysis</title><p>Flow cytometry immunophenotyping of bone marrow aspirates at diagnosis and during follow-up was performed centrally in the Croatian Reference Centre for Immunodiagnostics of Hematological and Immunological Diseases, University Hospital Center Zagreb. Diagnostic bone marrow samples were collected before treatment and processed within 24 hours according to the standard procedure elaborated in Supplemental Methods<xref rid="S6" ref-type="supplementary-material">(Supplemental Methods)</xref>. LAIPs of leukemic blasts at diagnosis were determined and reported for each antigen according to AIEOP-BFM Consensus Guidelines 2016 for ALL immunophenotyping (<xref rid="R16" ref-type="bibr">16</xref>) (Supplemental Methods<xref rid="S6" ref-type="supplementary-material">(Supplemental Methods)</xref>).</p></sec><sec><title>Minimal residual disease assessment by flow cytometry</title><p>FCM-MRD was measured in bone marrow on day 15 of induction therapy after 14 days of prednisone, vincristine, daunorubicin, asparaginase, and intrathecal methotrexate. All samples were processed according to stain/lyse protocol, using BD FACS<sup>TM</sup> Lysing Solution and analyzed using a FacsCalibur flow cytometer and Paint-a-Gate<sup>TM</sup> software (all from BD Biosciences, San Jose, CA, USA), as previously described (<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R26" ref-type="bibr">26</xref>). LAIPs of leukemic lymphoblasts were identified at diagnosis as deviations from normal lymphocyte differentiation/maturation patterns defined by previously published immunophenotypes of hematogones (<xref rid="R27" ref-type="bibr">27</xref>). For this purpose, the following monoclonal fluorochrome-conjugated antibody combinations were used: 1) SYTO16/CD10-PE/CD45-PerCP/CD19-APC; 2) CD20-FITC/CD10-PE/CD34-PerCP-Cy5.5/CD19-APC; 3) CD58-FITC/CD10-PE/CD45-PerCP/CD19-APC; and 4) CD10&#x02009;+&#x02009;20-FITC/CD38-PE/CD45-PerCP/CD19-APC for BCP-ALL; and 1) SYTO16/CD7-PE/CD45-PerCP/CD3-APC; 2) CD99-FITC/CD7-PE/CD5-PerCP-Cy5.5/CD3-APC; 3) TdT-FITC/CD7-PE/CD3-PerCP/citCD3-APC; and 4) CD4-FITC/CD8-PE/CD45-PerCP/CD3-APC for T-ALL. The same panels were used during the follow-up for FCM-MRD detection. The presence of nonnucleated cells (platelets, red cell fragments, and debris) and hemodilution was corrected using the cell-permeant nucleic acid-binding dye SYTO16. A total of 300&#x02009;000 nucleated (SYTO16+) events were acquired. Samples with significant hemodilution, defined as having less than 2% erythroblasts (SYTO16+CD45-lineage-) or fewer than 50% SYTO16+ events, were excluded from patient stratification. FCM-MRD is quantified as the percentage of leukemic cells among nucleated (SYTO16+) cells.</p></sec><sec><title>Cytogenetic and molecular analysis</title><p>Conventional cytogenetic and fluorescence <italic>in situ</italic> hybridization (FISH) with commercially available probe sets were performed routinely on bone marrow samples prior to therapy (<xref rid="R28" ref-type="bibr">28</xref>). Karyotypes were described according to the International System of Human Cytogenetic Nomenclature (ISCN, 2009) (<xref rid="R29" ref-type="bibr">29</xref>). The presence of <italic>BCR::ABL1, KMT2A::AFF1, ETV6::RUNX1</italic>, and <italic>TCF3::PBX1</italic> fusion gene transcripts was examined as part of routine ALL molecular diagnostics using standardized reverse transcription-polymerase chain reaction (RT-PCR) analysis, following the BIOMED-1 protocol (<xref rid="R30" ref-type="bibr">30</xref>).</p></sec><sec><title>Statistical analysis</title><p>Differences between patient groups were assessed with &#x003c7;<sup>2</sup> or Fisher exact tests for categorical variables and the Mann-Whitney U test for continuous variables. Statistical details are provided in Supplemental Methods<xref rid="S6" ref-type="supplementary-material">(Supplemental Methods)</xref>. The primary endpoint of the study was the day 15 FCM-MRD in bone marrow, categorized as a dichotomous variable (FCM-MRD&#x0003c;10% vs FCM-MRD&#x02265;10%). Logistic regression was conducted to identify LAIP and other independent predictors of FCM-MRD&#x02265;10%. Associations between FCM-MRD and assessed variables were expressed as odds ratios (OR) with 95% confidence intervals (CI). Receiver operating characteristic (ROC) curves and the area under the curve (AUC) were used to assess the discriminatory ability of predictors. The Kaplan-Meier method with log-rank tests for group comparisons was used to estimate survival rates. Event-free survival (EFS) and overall survival (OS) were calculated from the date of diagnosis to relapse, resistance, second malignant neoplasm, and/or death alone. The cumulative incidence of relapse (CIR) was compared between groups using a Gray's test, considering death before relapse as a competing risk. Patients&#x02019; follow-up data were updated in June 2023. Two-tailed <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant. Statistical analyses were performed with SPSS, version 26 (IBM, Armonk, NY, USA), and SAS OnDemand for Academics (SAS Institute Inc., Cary, NC, USA).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Clinical and biological characteristics of Croatian pediatric ALL patients</title><p>The median age at diagnosis was 5.2 years (range, 0-17.5 years), with a predominance of boys (61.3%). The highest proportion of patients was in the age group 1-6 years (n&#x02009;=&#x02009;214; 54.5%), while the lowest was in the age group 16-18 years (n&#x02009;=&#x02009;15; 3.8%) and in the infant group (n&#x02009;=&#x02009;12; 3.1%) (<xref rid="T1" ref-type="table">Table 1</xref>, Supplemental Table 1<xref rid="S7" ref-type="supplementary-material">(Supplemental Table 1)</xref>, and Supplemental Table 2<xref rid="S8" ref-type="supplementary-material">(Supplemental Table 2)</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Patients&#x02019; characteristics according to immunophenotype (BCP-ALL vs T-ALL)*</p></caption><table frame="hsides" rules="groups"><col width="144" span="1"/><col width="4" span="1"/><col width="79" span="1"/><col width="82" span="1"/><col width="88" span="1"/><col width="48" span="1"/><thead><tr><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">
<hr/>
</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Total</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">BCP-ALL</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">T-ALL</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">P<sup>&#x02020;</sup></th></tr></thead><tbody><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">n (%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">393 (100.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">326 (83.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">67 (17.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="left" scope="row" rowspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">n (%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">n (%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">n (%)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="left" scope="row" rowspan="1">
<bold>Sex</bold>
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.057<hr/></td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">male<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">241 (61.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">193 (59.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">48 (71.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">female<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">152 (38.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">133 (40.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">19 (28.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="left" scope="col" rowspan="1"><bold>Age</bold> (years)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">median (range)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5.2 (0.0&#x02013;17.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4.6 (0.0&#x02013;17.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">9.2 (1.6&#x02013;17.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001<sup>&#x02021;</sup><hr/></td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">&#x0003c;1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">12 (3.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">12 (3.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0 (0.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001<hr/></td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">&#x02265;1 &#x02013;&#x0003c;6<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">214 (54.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">193 (59.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">21 (31.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">&#x02265;6 &#x02013;&#x0003c;10<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">62 (15.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">49 (15.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">13 (19.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">&#x02265;10 &#x02013;&#x0003c;16<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">90 (22.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">64 (19.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">26 (38.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">&#x02265;16 &#x02013;&#x0003c;18<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">15 (3.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8 (2.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7 (10.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="left" scope="row" rowspan="1"><bold>WBC count</bold> (&#x02009;&#x000d7;&#x02009;10<sup>9</sup>/L)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001<hr/></td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">&#x0003c;20<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">234 (60.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">222 (69.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">12 (18.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">&#x02265;20<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">152 (39.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">98 (30.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">54 (81.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">no information<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="left" scope="row" rowspan="1">
<bold>CNS status</bold>
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.109<hr/></td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">CNS1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">355 (92.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">299 (93.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">56 (87.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">CNS2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">20 (5.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">16 (5.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 (6.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">CNS3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10 (2.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6 (1.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 (6.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">No information<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="left" scope="row" rowspan="1">
<bold>Splenomegaly</bold>
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.006<hr/></td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">no<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">188 (49.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">166 (52.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">22 (33.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">yes<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">193 (50.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">150 (47.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">43 (66.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">no information<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">12<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="left" scope="row" rowspan="1">
<bold>Hepatomegaly</bold>
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.657<hr/></td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">no<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">150 (39.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">126 (39.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">24 (36.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">yes<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">231 (60.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">190 (60.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">41 (63.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">no information<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">12<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="left" scope="row" rowspan="1">
<bold>Mediastinal mass</bold>
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001<hr/></td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">no<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">340 (90.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">309 (99.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">31 (48.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">yes<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">36 (9.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 (1.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">33 (51.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">no information<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">17<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">14<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="left" scope="row" rowspan="1">
<bold>Testicular involvement</bold>
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.347<hr/></td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">no<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">233 (99.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">189 (99.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">44 (97.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">yes<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 (0.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 (0.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 (2.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">no information<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="4" valign="top" align="left" scope="row" rowspan="1">
<bold>Genetic prognostic groups</bold>
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001<hr/></td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">favorable<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">105 (27.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">104 (32.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 (1.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">intermediate<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">245 (64.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">188 (58.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">57 (93.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">poor<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">31 (8.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">28 (8.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 (4.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">no information<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">12<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="left" scope="row" rowspan="1">
<bold>Relapse</bold>
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.338<hr/></td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">no<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">340 (87.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">285 (87.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">55 (83.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">yes<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">51 (13.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">40 (12.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11 (16.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">no information<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="left" scope="row" rowspan="1">
<bold>Site of relapse</bold>
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.095<hr/></td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">isolated BM<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">33 (64.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">28 (70.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5 (45.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">isolated CNS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8 (15.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 (10.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 (36.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">isolated testicular<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 (3.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 (2.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 (9.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="center" scope="row" rowspan="1">combined<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8 (15.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7 (17.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 (9.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="3" valign="top" align="left" scope="row" rowspan="1"><bold>Time to relapse</bold> (months from diagnosis)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.006<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">very early (less than 18)<hr/></td><td colspan="2" valign="top" align="center" rowspan="1">20 (39.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11 (27.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">9 (81.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">early (18-30)<hr/></td><td colspan="2" valign="top" align="center" rowspan="1">11 (21.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11 (27.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0 (0.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">late (more than 30)<hr/></td><td colspan="2" valign="top" align="center" rowspan="1">20 (39.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">18 (45.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 (18.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<bold>Death</bold>
<hr/>
</td><td colspan="2" valign="top" align="left" rowspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.186<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">no<hr/></td><td colspan="2" valign="top" align="center" rowspan="1">331 (84.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">278 (85.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">53 (79.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">yes<hr/></td><td colspan="2" valign="top" align="center" rowspan="1">61 (15.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">47 (14.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">14 (20.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">no information<hr/></td><td colspan="2" valign="top" align="center" rowspan="1">1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">
<bold>HSCT</bold>
<hr/>
</td><td colspan="2" valign="top" align="left" rowspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">matched related donor (brother/sister)<hr/></td><td colspan="2" valign="top" align="center" rowspan="1">22 (54.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">13 (46.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">9 (69.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">mismatched related donor<hr/></td><td colspan="2" valign="top" align="center" rowspan="1">1 (2.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0 (0.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 (7.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">matched unrelated donor<hr/></td><td colspan="2" valign="top" align="center" rowspan="1">18 (43.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">15 (53.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 (23.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">
<bold>Protocols</bold>
<hr/>
</td><td colspan="2" valign="top" align="left" rowspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">ALL IC-BFM 2002<hr/></td><td colspan="2" valign="top" align="center" rowspan="1">196 (49.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">150 (46.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">46 (68.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">ALL IC-BFM 2009<hr/></td><td colspan="2" valign="top" align="center" rowspan="1">183 (46.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">162 (49.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">21 (31.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">INTERFANT 99/06<hr/></td><td colspan="2" valign="top" align="center" rowspan="1">12 (3.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">12 (3.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0 (0.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Continued treatment abroad</td><td colspan="2" valign="top" align="center" rowspan="1">2 (0.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 (0.6)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0.0)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>*Abbreviations: ALL &#x02013; acute lymphoblastic leukemia; BCP &#x02013; B-cell precursor; BM &#x02013; bone marrow; CNS &#x02013; central nervous system; HSCT &#x02013; hematopoietic stem cell transplantation; WBC &#x02013; white blood cells.</p><p>&#x02020;&#x003c7;<sup>2</sup> or Monte Carlo simulated Fisher exact test comparing BCP- and T-ALL groups; patients with no information were excluded from the analysis.</p><p>&#x02021;Mann-Whitney U test.</p></table-wrap-foot></table-wrap><p>Conventional cytogenetics was successfully performed in 374 patients (95.2%). Normal karyotype was identified in 73 patients (19.5%). The most frequent recurrent abnormalities were high hyperdiploidy (51-65 chromosomes) in 94 (25.1%) and t (12;21) ETV6::RUNX1 in 70 (18.7%) patients, followed by mixed-lineage leukemia (MLL) gene rearrangements in 14 (3.7%), t (9;22) BCR::ABL1 in 8 (2.1%), t (1;19) <italic>TCF3::PBX1</italic> in 4 (1.1%), and hypodiploidy (&#x0003c;44 chromosomes) in 4 patients (1.1%). The &#x0201c;other&#x0201d; category (28.7%) comprises all the remaining cytogenetic abnormalities (<xref rid="F1" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="F1" fig-type="figure"><label>Figure 1</label><caption><p>The frequency of major cytogenetic subgroups in Croatian children with acute lymphoblastic leukemia (ALL), shown for (<bold>A</bold>) the cohort with available cytogenetic results (N&#x02009;=&#x02009;374) and (<bold>B</bold>) patients with mixed-lineage leukemia (MLL) rearrangements (N&#x02009;=&#x02009;14).</p></caption><graphic xlink:href="CroatMedJ_66_0100-F1" position="float"/></fig><p>High hyperdiploidy and t (12;21) were predominantly found in the age group 1-6 years (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), whereas <italic>MLL</italic> gene rearrangements were predominantly found in infants, representing 58.3% of all infant ALL cases (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) (Supplemental Figure 1A<xref rid="S1" ref-type="supplementary-material">(Supplemental Figure 1)</xref>).</p><p>According to cytogenetic and molecular criteria, patients were categorized into three prognostic groups: favorable (high hyperdiploidy and t (12;21) without other abnormalities; n&#x02009;=&#x02009;105; 27.6%), poor (MLL rearrangements, t (9;22), hypodiploidy, t (17;19), 17p abnormalities, and 13q loss; n&#x02009;=&#x02009;31; 8.1%), and intermediate (all other genetic abnormalities; n&#x02009;=&#x02009;245; 64.3%).</p><p>Most patients (n&#x02009;=&#x02009;326; 83%) had B-cell precursor (BCP) ALL, while 67 patients (17%) had T-cell ALL (T-ALL). The latter were significantly older, had higher WBC, a higher frequency of splenomegaly and mediastinal masses, less favorable genetics, and a higher incidence of a very early relapse (<xref rid="T1" ref-type="table">Table 1</xref>; Supplemental Figure 2<xref rid="S2" ref-type="supplementary-material">(Supplemental Figure 2)</xref>).</p><p>According to EGIL, most BCP-ALL cases were classified as the &#x0201c;common&#x0201d; subtype (B-II; n&#x02009;=&#x02009;235; 72.1%), followed by pre-B (B-III; n&#x02009;=&#x02009;76; 23.3%) and pro-B (B-I; n&#x02009;=&#x02009;15; 4.6%) subtype. Pro-B patients were mostly infants (53%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) and had significantly higher WBC, CNS3 status, and poor prognostic genetic abnormalities (Supplemental Table 1<xref rid="S7" ref-type="supplementary-material">(Supplemental Table 1)</xref>).</p><p>The &#x0201c;common&#x0201d; ALL was significantly associated with high hyperdiploidy (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), and the pro-B immunophenotype with <italic>MLL</italic> gene rearrangements (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), primarily t (4;11) (10 of 14 cases). Most patients with t (1;19) translocation (3 of 4) had a pre-B immunophenotype; however, this association did not reach statistical significance (Supplemental Figure 1B<xref rid="S1" ref-type="supplementary-material">(Supplemental Figure 1)</xref>).</p><p>In T-ALL, the most common subtype was cortical T-ALL (T-III; n&#x02009;=&#x02009;30; 44.7%), followed by pre-T (T-II; n&#x02009;=&#x02009;16; 23.9%), mature T-ALL (T-IV; n&#x02009;=&#x02009;12; 17.9%), and pro-T (T-I; n&#x02009;=&#x02009;4; 6%). These patients did not differ in clinical or genetic characteristics at diagnosis, except for a significant association between mediastinal mass and the cortical immunophenotype (Supplemental Table 2<xref rid="S8" ref-type="supplementary-material">(Supplemental Table 2)</xref>).</p></sec><sec><title>Treatment outcomes and risk group distribution</title><p>Of 379 non-infant patients, 196 (51.7%) were treated according to the ALL IC-BFM 2002 protocol and 183 (48.3%) according to the ALL IC-BFM 2009 protocol. The median follow-up was 80.3 months for ALL IC-BFM 2002 and 76.8 months for ALL IC-BFM 2009. Forty-nine patients relapsed (13%) and 56 patients (14.8%) died (<xref rid="T2" ref-type="table">Table 2</xref>). No significant differences in survival were observed between the protocols. The 5-year event-free survival (EFS &#x000b1; SE) was 82.1%&#x02009;&#x000b1;&#x02009;2.8% for ALL IC-BFM 2002 and 81.7%&#x02009;&#x000b1;&#x02009;2.9% for ALL IC-BFM 2009 (<italic>P</italic>&#x02009;=&#x02009;0.656). The 5-year overall survival (OS &#x000b1; SE) was 88.0%&#x02009;&#x000b1;&#x02009;2.3% and 85.0%&#x02009;&#x000b1;&#x02009;2.7%, respectively (<italic>P</italic>&#x02009;=&#x02009;0.571) (<xref rid="F2" ref-type="fig">Figures 2A and 2B</xref>). The 5-year cumulative incidence of relapse (CIR &#x000b1; SE) was higher in ALL IC-BFM 2002 but not significantly so (12.3%&#x02009;&#x000b1;&#x02009;2.4% vs 10%&#x02009;&#x000b1;&#x02009;2.3%; <italic>P</italic>&#x02009;=&#x02009;0.250) (<xref rid="F3" ref-type="fig">Figure 3</xref>). Relapses were classified as very early (within 18 months from diagnosis; 38.8%), early (18-30 months; 20.4%), and late (&#x0003e;30 months from diagnosis; 40.8%) (<xref rid="T2" ref-type="table">Table 2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Early response characteristics, risk group distribution, and outcomes of patients treated with the ALL IC-BFM 2002 and ALL IC-BFM 2009 protocols*</p></caption><table frame="hsides" rules="groups"><col width="155" span="1"/><col width="70" span="1"/><col width="92" span="1"/><col width="91" span="1"/><col width="42" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">
<hr/>
</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">
<hr/>
</th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Protocols<hr/></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">
<hr/>
</th></tr><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">
<hr/>
</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Total<hr/></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">ALL IC-BFM 2002<hr/></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">ALL IC-BFM 2009<hr/></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">P&#x02020;<hr/></th></tr><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1">n (%)<hr/></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">379 (100.0)<hr/></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">196 (51.7)<hr/></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">183 (48.3)<hr/></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">
<hr/>
</th></tr><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"/><th valign="top" align="center" scope="col" rowspan="1" colspan="1">n (%)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">n (%)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">n (%)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<bold>Prednisone response day 8</bold>
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.087<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">GPR<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">344 (93.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">173 (91.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">171 (95.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">PPR<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">25 (6.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">17 (8.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8 (4.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">no information<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<bold>BM morphology day 15</bold>
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.014<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">M1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">266 (77.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">134 (72.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">132 (84.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">M2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">54 (15.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">34 (18.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">20 (12.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">M3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">23 (6.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">18 (9.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5 (3.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">no information<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">36<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">26<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">
<bold>FCM-MRD day 15</bold>
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">MRD&#x0003c;0.1%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">n/a<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">38 (27.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">MRD 0.1%-10%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">n/a<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">68 (49.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">MRD&#x02265;10%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">n/a<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">32 (23.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">no information/inadequate sample<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">45<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<bold>FCM-MRD day 15</bold>
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.692<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">MRD&#x0003c;10%<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">239 (77.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">133 (78.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">106 (76.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">MRD&#x02265;10%<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">68 (22.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">36 (21.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">32 (23.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">no information/inadequate sample<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">72<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">27<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">45<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<bold>Risk group</bold>
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">SR<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">82 (21.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">60 (30.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">22 (12.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">IR<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">218 (58.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">98 (50.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">120 (65.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">HR<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">76 (20.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">36 (18.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">40 (22.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">not stratified<sup>&#x02021;</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">
<bold>Relapse</bold>
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">no<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">328 (87.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">167 (85.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">161 (89.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.280<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">yes<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">49 (13.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">29 (14.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">20 (11.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="left" scope="row" rowspan="1"><bold>Time to relapse</bold> (months from diagnosis)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.290<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">very early (less than 18)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">19 (38.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11 (37.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8 (40.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">early (18&#x02013;30)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10 (20.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 (13.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6 (30.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">late (more than 30)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">20 (40.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">14 (48.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6 (30.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<bold>Death</bold>
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.570<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">no<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">323 (85.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">169 (86.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">154 (84.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">yes</td><td valign="top" align="center" rowspan="1" colspan="1">56 (14.8)</td><td valign="top" align="center" rowspan="1" colspan="1">27 (13.8)</td><td valign="top" align="center" rowspan="1" colspan="1">29 (15.8)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>*Abbreviations: ALL &#x02013; acute lymphoblastic leukemia; BM &#x02013; bone marrow; FCM &#x02013; flow cytometry; GPR &#x02013; good prednisone response (&#x0003c;1000 blasts/&#x003bc;L in peripheral blood on day 8); HR &#x02013; high risk; IC-BFM &#x02013; international consortium Berlin&#x02013;Frankfurt&#x02013;M&#x000fc;nster; IR &#x02013; intermediate risk; M1 &#x02013;&#x0003c;5% blasts; M2 &#x02013; 5&#x02013;25% blasts; M3 &#x02013;&#x02265;25% blasts in bone marrow; MRD &#x02013; minimal residual disease; PPR &#x02013; poor prednisone response (&#x02265;1000 blasts/&#x003bc;L in peripheral blood on day 8); SR &#x02013; standard risk.</p><p>&#x02020;&#x003c7;<sup>2</sup> test; patients without data or with an inadequate sample were excluded from the analysis.</p><p>&#x02021;Patients died during or immediately after the induction phase of treatment.</p></table-wrap-foot></table-wrap><fig position="float" id="F2" fig-type="figure"><label>Figure 2</label><caption><p>Kaplan-Meier survival curves for (<bold>A</bold>) event-free survival (EFS) and (<bold>B</bold>) overall survival (OS) in non-infant patients (aged 1&#x02013;18 years) treated according to the ALL IC-BFM 2002 and ALL IC-BFM 2009 protocols. ALL &#x02013; acute lymphoblastic leukemia; IC-BFM &#x02013; international consortium Berlin&#x02013;Frankfurt&#x02013;M&#x000fc;nster.</p></caption><graphic xlink:href="CroatMedJ_66_0100-F2" position="float"/></fig><fig position="float" id="F3" fig-type="figure"><label>Figure 3</label><caption><p>Cumulative incidence of relapse (CIR) in non-infant patients (aged 1&#x02013;18 years) treated according to the ALL IC-BFM 2002 and ALL IC-BFM 2009 protocols. ALL &#x02013; acute lymphoblastic leukemia; IC-BFM &#x02013; international consortium Berlin&#x02013;Frankfurt&#x02013;M&#x000fc;nster.</p></caption><graphic xlink:href="CroatMedJ_66_0100-F3" position="float"/></fig><p>In the ALL IC-BFM 2002 protocol, patients were classified into risk groups as follows: 60 (30.9%) in the standard-risk, 98 (50.5%) in the intermediate-risk, and 36 (18.6%) in the high-risk group (<xref rid="T2" ref-type="table">Table 2</xref>). Survival outcomes differed significantly among all risk groups (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 for both EFS and OS): the 5-year EFS and OS were 92.8%&#x02009;&#x000b1;&#x02009;3.5% and 98.0%&#x02009;&#x000b1;&#x02009;2.0% in the standard-risk group; 86.1%&#x02009;&#x000b1;&#x02009;3.6% and 92.8%&#x02009;&#x000b1;&#x02009;2.6% in the intermediate-risk; and 57.8%&#x02009;&#x000b1;&#x02009;8.3% and 62.9%&#x02009;&#x000b1;&#x02009;8.2% in the high-risk group, respectively (Supplemental Figures 3A and 3B<xref rid="S3" ref-type="supplementary-material">(Supplemental Figure 3)</xref>). Among the three risk groups, the 5-year CIR values were 7.2%&#x02009;&#x000b1;&#x02009;3.5%, 9.8%&#x02009;&#x000b1;&#x02009;3.1%, and 28.3%&#x02009;&#x000b1;&#x02009;7.7%, respectively (<italic>P</italic>&#x02009;=&#x02009;0.004). Pairwise comparisons of CIR revealed significant differences between the standard and high-risk group (<italic>P</italic>&#x02009;=&#x02009;0.001) and between the intermediate and high-risk group (<italic>P</italic>&#x02009;=&#x02009;0.022), but not between the standard and intermediate-risk group (<italic>P</italic>&#x02009;=&#x02009;0.148) (Supplemental Figure 4A<xref rid="S4" ref-type="supplementary-material">(Supplemental Figure 4)</xref>).</p><p>Day 15 FCM-MRD was introduced as an additional risk stratification criterion in the ALL IC-BFM 2009 protocol, which resulted in a significant reallocation of patients across risk groups: 22 (12.1%) in the standard-risk, 120 (65.9%) in the intermediate-risk, and 40 (22.0%) in the high-risk group (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) (<xref rid="T2" ref-type="table">Table 2</xref>). The EFS, OS, and CIR were 95.5%&#x02009;&#x000b1;&#x02009;4.4%, 95.0%&#x02009;&#x000b1;&#x02009;4.9%, and 4.6%&#x02009;&#x000b1;&#x02009;4.6% in the standard-risk; 84.6%&#x02009;&#x000b1;&#x02009;3.3%, 89.0%&#x02009;&#x000b1;&#x02009;2.9%, and 8.7%&#x02009;&#x000b1;&#x02009;2.7% in the intermediate-risk; and 67.5%&#x02009;&#x000b1;&#x02009;7.4%, 70.0%&#x02009;&#x000b1;&#x02009;7.2%, and 20%&#x02009;&#x000b1;&#x02009;6.4% in the high-risk group, respectively. Survival differed significantly between risk groups, except between the standard-risk and intermediate-risk group for EFS (<italic>P</italic>&#x02009;=&#x02009;0.167) and OS (<italic>P</italic>&#x02009;=&#x02009;0.264) (Supplemental Figures 3C and 3D<xref rid="S3" ref-type="supplementary-material">(Supplemental Figure 3)</xref>). Pairwise comparison of CIR showed no significant differences between the high-risk group and the standard-risk group (<italic>P</italic>&#x02009;=&#x02009;0.092) or the intermediate-risk group (<italic>P</italic>&#x02009;=&#x02009;0.052) (Supplemental Figure 4B<xref rid="S4" ref-type="supplementary-material">(Supplemental Figure 4)</xref>).</p></sec><sec><title>Association of day 15 FCM-MRD&#x02265;10% with patients&#x02019; characteristics</title><p>Of the 379 non-infant patients enrolled in the ALL IC-BFM 2002/2009 protocols, 72 (19%) lacked FCM-MRD data. Among the remaining patients, 68 (22.1%) had FCM-MRD&#x02265;10% (Supplemental Table 3<xref rid="S9" ref-type="supplementary-material">(Supplemental Table 3)</xref>). FCM-MRD&#x02265;10% was significantly associated with older age, higher WBC at diagnosis, and relapse, in BCP-ALL but not in T-ALL. Regarding the cytomorphological response to therapy, FCM-MRD&#x02265;10% was significantly associated with poor prednisone response (PPR) on day 8 and M2/M3 bone marrow on day 15 in both BCP- and T-ALL (Supplemental Table 4<xref rid="S10" ref-type="supplementary-material">(Supplemental Table 4)</xref>).</p></sec><sec><title>Association of day 15 FCM-MRD&#x02265;10% with LAIPs</title><p>FCM-MRD&#x02265;10% levels did not differ between BCP- and T-ALL or among the EGIL immunophenotypic categories, although PPR and M3 bone marrow were significantly associated with T-ALL (Supplemental Table 3<xref rid="S9" ref-type="supplementary-material">(Supplemental Table 3)</xref> and Supplemental Table 4<xref rid="S10" ref-type="supplementary-material">(Supplemental Table 4)</xref>).</p><p>A preliminary analysis of the association between LAIPs and FCM-MRD levels is shown in Supplemental Table 5<xref rid="S11" ref-type="supplementary-material">(Supplemental Table 5)</xref> and Supplemental Table 6<xref rid="S12" ref-type="supplementary-material">(Supplemental Table 6)</xref>. Due to the immunophenotypic heterogeneity of individual CD marker expression and the limited number of events within LAIP categories, most expression categories in BCP-ALL were pooled into two clusters: negative/weak (negative/dim/partially positive 1) and strong (medium/heterogeneous/bright/partially positive 2). In BCP-ALL, FCM-MRD&#x02265;10% was significantly associated with CD19<sup>dim</sup>, CD34<sup>strong</sup>, CD45<sup>strong</sup>, and the myeloid marker CD13<sup>strong</sup> (Supplemental Table 5<xref rid="S11" ref-type="supplementary-material">(Supplemental Table 5)</xref>).</p><p>To identify predictive indicators of poor response to treatment, multivariate logistic regression included all significant pre-treatment variables from the univariate analysis: age, WBC count, CD13, CD19, CD34, and CD45, along with sex and genetic prognostic groups, both of which were at the limit of statistical significance (<italic>P</italic>&#x02009;=&#x02009;0.065 and <italic>P</italic>&#x02009;=&#x02009;0.062, respectively) (<xref rid="T3" ref-type="table">Table 3</xref>). After adjustment, WBC&#x02265;20&#x02009;&#x000d7;&#x02009;10<sup>9</sup>/L (OR 2.870; 95% CI 1.276&#x02013;6.456; <italic>P</italic>&#x02009;=&#x02009;0.011), CD13<sup>strong</sup> (OR 5.005; 95% CI 1.888&#x02013;13.272; <italic>P</italic>&#x02009;=&#x02009;0.001), and CD34<sup>strong</sup> (OR 4.183; 95% CI 1.129&#x02013;15.500; <italic>P</italic>&#x02009;=&#x02009;0.032) remained significant and independent predictors of day 15 FCM-MRD&#x02265;10%. The combined score of these three predictors demonstrated good discriminatory power (AUC 0.728; 95% CI: 0.647&#x02013;0.809) (Supplemental Figure 5A<xref rid="S5" ref-type="supplementary-material">(Supplemental Figure 5)</xref>). These predictors retained their significance even after excluding patients from the poor genetic prognostic group (Supplemental Table 7<xref rid="S13" ref-type="supplementary-material">(Supplemental Table 7)</xref>), with a slightly higher AUC of 0.734 (95% CI: 0.651&#x02013;0.817) (Supplemental Figure 5B<xref rid="S5" ref-type="supplementary-material">(Supplemental Figure 5)</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Univariate and multivariate logistic regression analyses for predictors of high FCM-MRD (&#x02265;10%) on day 15 in BCP-ALL patients treated with ALL IC-BFM 2002/2009 protocols*</p></caption><table frame="hsides" rules="groups"><col width="101" span="1"/><col width="65" span="1"/><col width="72" span="1"/><col width="50" span="1"/><col width="63" span="1"/><col width="68" span="1"/><col width="39" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1">
<bold>Variable</bold>
<hr/>
</th><th colspan="3" valign="top" align="center" scope="colgroup" rowspan="1">
<bold>Univariate logistic regression</bold>
<hr/>
</th><th colspan="3" valign="top" align="center" scope="colgroup" rowspan="1">
<bold>Multivariate logistic regression</bold>
<hr/>
</th></tr><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"/><th valign="top" align="center" scope="col" rowspan="1" colspan="1">
<bold>OR</bold>
</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">
<bold>95% CI</bold>
</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">
<bold>P</bold>
</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">
<bold>OR</bold>
</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">
<bold>95% CI</bold>
</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">
<bold>P</bold>
</th></tr></thead><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Male sex<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.869<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.962&#x02013;3.629<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.065<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.770<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.782&#x02013;4.005<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.170<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Age &#x02265;6 years<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.226<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.193&#x02013;4.155<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.012<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.294<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.530&#x02013;3.159<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.572<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">WBC&#x02265;20x10<sup>9</sup>/L<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.809<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.490&#x02013;5.298<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.001<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.870<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.276&#x02013;6.456<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.011<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">EGIL subtype<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">pro-B (B-I)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Reference<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">common (B-II)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.282<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.017&#x02013;4.603<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.374<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">pre-B (B-III)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.157<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.009&#x02013;2.767<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.206<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td colspan="2" valign="top" align="left" scope="col" rowspan="1">Genetic prognostic group<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">favorable<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Reference<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">Reference<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">intermediate<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.092<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.553&#x02013;2.156<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.800<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.046<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.455&#x02013;2.401<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.916<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">poor<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3.042<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.948&#x02013;9.762<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.062<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.756<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.282&#x02013;10.934<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.546<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Antigen<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">CD10 N/weak<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.313<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.134&#x02013;12.896<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.815<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">CD13 strong<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3.681<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.636&#x02013;8.280<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.002<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5.005<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.888&#x02013;13.272<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.001<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">CD19 weak<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5.589<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.210&#x02013;25.819<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.028<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3.810<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.498&#x02013;29.141<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.198<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">CD20 strong<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.993<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.505&#x02013;1.953<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.983<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">CD33 strong<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.371<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.631&#x02013;2.980<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.425<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">CD34 strong<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5.848<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.747&#x02013;19.575<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.004<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4.183<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.129&#x02013;15.500<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.032<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">CD45 strong<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4.244<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.302&#x02013;13.834<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.017<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.816<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.639&#x02013;12.408<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.171<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">CD117 strong<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.347<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.134&#x02013;13.530<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.800<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">CD58 overexpressed<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.475<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.167&#x02013;13.039<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.726<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">TdT N/weak</td><td valign="top" align="center" rowspan="1" colspan="1">0.520</td><td valign="top" align="center" rowspan="1" colspan="1">0.149&#x02013;1.818</td><td valign="top" align="center" rowspan="1" colspan="1">0.306</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>*Abbreviations: ALL &#x02013; acute lymphoblastic leukemia; CI &#x02013; confidence interval; EGIL &#x02013; European Group for Immunological Classification of Leukemias; FCM-MRD &#x02013; flow cytometry minimal residual disease IC-BFM &#x02013; international consortium Berlin&#x02013;Frankfurt&#x02013;M&#x000fc;nster N &#x02013; negative; OR &#x02013; odds ratio; WBC &#x02013; white blood cells.</p></table-wrap-foot></table-wrap><p>Blasts in T-ALL exhibited less heterogeneous immunophenotypic aberrations; therefore, the expression of their CD markers was reported qualitatively as negative or positive. A significant association was found between FCM-MRD&#x02265;10% and CD8<sup>negative</sup>, CD10<sup>negative</sup>, CD34<sup>positive</sup>, TdT<sup>N/dim</sup>, and the myeloid markers CD33<sup>positive</sup> and CD117<sup>positive</sup> (Supplemental Table 6<xref rid="S12" ref-type="supplementary-material">(Supplemental Table 6)</xref>). Due to the small number of T-ALL patients and events, a multivariate analysis could not be performed.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Our study provides the first overview of the characteristics and outcomes of Croatian pediatric ALL patients diagnosed and treated between 2003 and 2017. The main findings confirmed a high predominance of BCP-ALL cases, a peak incidence in preschool age, and a slight male predominance, consistent with previous reports (<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R31" ref-type="bibr">31</xref>,<xref rid="R32" ref-type="bibr">32</xref>). The distribution of EGIL immunophenotypic subtypes, WHO-defined recurrent genetic aberrations, and their mutual association aligned with published data (<xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R33" ref-type="bibr">33</xref>-<xref rid="R37" ref-type="bibr">37</xref>). Taken together, our findings support the reproducibility of the EGIL classification as a clinically relevant tool for diagnostics, characterization of ALL patient cohorts, and initial prognostic guidance (<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref>).</p><p>The survival outcomes of ALL IC-BFM 2002 and ALL IC-BFM 2009 protocols in our cohort were comparable to those reported by major collaborative study groups worldwide (<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R38" ref-type="bibr">38</xref>-<xref rid="R40" ref-type="bibr">40</xref>).</p><p>In alignment with the overall results of the intercontinental ALL IC-BFM study group (<xref rid="R11" ref-type="bibr">11</xref>), the implementation of standardized FCM-MRD detection on day 15 in ALL IC-BFM 2009 led to significant differences in risk-group distribution, however without substantial differences in the outcomes between the two protocols, probably due to similar treatment intensity in both studies. Our CIR rates were slightly lower in the ALL IC-BFM 2009 protocol (10% vs 12.3%), particularly in the standard-risk (4.6% vs 7.2%) and high-risk group (20% vs 28.3%). This reduction likely reflects the impact of FCM-MRD introduction on risk stratification and, subsequently, stricter risk group assignments (which led to the reallocation of patients from the standard-risk group to the intermediate-risk group) and advancements in supportive care. In this context, when comparing FCM-MRD and morphology on day 15, we found some discrepant cases in which 18 M1 patients had FCM-MRD&#x02265;10% (data not shown). This indicates that morphological findings should be interpreted with caution, particularly when assessment is not centralized (<xref rid="R4" ref-type="bibr">4</xref>).</p><p>MRD provides early insights into individual therapy response, reflecting the combined impact of patient characteristics, leukemia cell biology, and therapy-related factors on blast reduction (<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R13" ref-type="bibr">13</xref>). Given these findings and considering that immunophenotype reflects the intrinsic properties of leukemic cells, we explored the predictive potential of pretreatment LAIPs for poor early response. The AEIOP-BFM ALL 2000 study first demonstrated that LAIP-based FCM-MRD analysis in bone marrow on day 15 was the most powerful early predictor of relapse, with high FCM-MRD (&#x02265;10%) associated with unfavorable outcomes (<xref rid="R4" ref-type="bibr">4</xref>).</p><p>To our knowledge, this is the first study to investigate the association between diagnostic LAIPs and FCM-MRD&#x02265;10% on day 15 in bone marrow, showing that the strong CD13 and CD34 expression and WBC count &#x02265;20&#x02009;&#x000d7;&#x02009;10<sup>9</sup>/L significantly predicts poor early treatment response in BCP-ALL, independent of other clinical and genetic risk factors.</p><p>Nowadays, LAIP analysis is a well-established method for FCM-MRD monitoring during treatment (6,8,9,17,18,26,41). Many studies have also investigated the prognostic significance of individual LAIP markers such as CD13 (<xref rid="R42" ref-type="bibr">42</xref>-<xref rid="R45" ref-type="bibr">45</xref>), CD20 (<xref rid="R46" ref-type="bibr">46</xref>-<xref rid="R50" ref-type="bibr">50</xref>), CD34 (<xref rid="R51" ref-type="bibr">51</xref>,<xref rid="R52" ref-type="bibr">52</xref>), or CD45 (<xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R46" ref-type="bibr">46</xref>,<xref rid="R53" ref-type="bibr">53</xref>), but often with conflicting results due to cohort heterogeneity, treatment regimens, and variations in FCM methodology and data interpretation. In contrast, few studies have focused on the direct association between LAIPs at diagnosis and MRD levels. In 2022, Modvig et al were the first to demonstrate an association between a CD34<sup>+</sup>CD38<sup>dim+</sup>nTdT<sup>dim+</sup> immunophenotype on leukemic blasts in Philadelphia (Ph)-negative BCP-ALL and poor therapy response, predicting a PCR-MRD&#x02265;10<sup>&#x02212;5</sup> at the end of induction (EOI) on day 29. Their study identified CD34<sup>high</sup> as the most significant independent predictor of EOI MRD, associated with an overrepresentation of genes related to stemness, cell migration, adhesion, and negative regulation of apoptosis (<xref rid="R54" ref-type="bibr">54</xref>).</p><p>In our study, CD13 was the most significant predictor of FCM-MRD&#x02265;10% in the entire BCP-ALL cohort. However, after excluding the poor genetic group, which included eight Ph-positive t (<xref rid="R9" ref-type="bibr">9</xref>;<xref rid="R22" ref-type="bibr">22</xref>) BCP-ALL patients, CD34 emerged as the most robust independent predictor, consistent with the findings of Modvig et al (<xref rid="R54" ref-type="bibr">54</xref>). CD13 is an N-aminopeptidase found on myeloid (<xref rid="R42" ref-type="bibr">42</xref>,<xref rid="R43" ref-type="bibr">43</xref>,<xref rid="R55" ref-type="bibr">55</xref>) and hematopoietic stem cells (<xref rid="R56" ref-type="bibr">56</xref>) and is often overexpressed in various types of cancers (<xref rid="R57" ref-type="bibr">57</xref>). Saxena et al demonstrated that CD13 was transiently expressed on a small subset of highly proliferative early B-cell precursors, while extended CD13 expression and dysregulation may trigger leukemogenesis and inhibit apoptosis (<xref rid="R55" ref-type="bibr">55</xref>). In BCP-ALL, CD13 expression was associated with t (<xref rid="R9" ref-type="bibr">9</xref>;<xref rid="R22" ref-type="bibr">22</xref>) and t (<xref rid="R12" ref-type="bibr">12</xref>;<xref rid="R21" ref-type="bibr">21</xref>) translocations (<xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R58" ref-type="bibr">58</xref>-<xref rid="R60" ref-type="bibr">60</xref>), but its prognostic value remained uncertain, with reports ranging from no significance (<xref rid="R42" ref-type="bibr">42</xref>) to poor prognosis in adults (<xref rid="R43" ref-type="bibr">43</xref>,<xref rid="R44" ref-type="bibr">44</xref>). One report involving 58 children with ALL identified high WBC and CD13 as significant predictors of poor early response on day 33 (<xref rid="R61" ref-type="bibr">61</xref>).</p><p>Altogether, the results mentioned above support the findings of our study. However, the retrospective design, relatively small and heterogeneous cohort, missing or incomplete data, and limited diagnostic panels of monoclonal antibodies may affect the generalizability of our findings. An important limitation of our study is the small number of T-ALL patients. As a result, analyses were limited to preliminary association tests, which identified a significant relationship between FCM-MRD&#x02265;10% and individual LAIPs (CD8<sup>negative</sup>, CD10<sup>negative</sup>, CD34<sup>positive</sup>, and the myeloid markers CD33<sup>positive</sup> and CD117<sup>positive</sup>), many of which are part of the diagnostic criteria for early T-cell precursor-ALL characterized by poor early response (<xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R21" ref-type="bibr">21</xref>).</p><p>In conclusion, our extensive retrospective study provides valuable insights into clinical-biological characteristics, early treatment response, and outcomes of Croatian pediatric ALL patients. The implementation of standardized FCM-MRD detection on day 15 in the ALL IC-BFM 2009 protocol led to more rigorous risk stratification, resulting in the reallocation of patients from the standard-risk to the intermediate-risk group, which in the future could be used for improved risk-based treatment. Furthermore, our findings underscore the potential of pretreatment immunophenotype as a predictor of poor early response in BCP-ALL. Our results warrant further validation in larger, well-designed prospective studies. Thus, understanding the leukemic cell properties could refine risk stratification, enhance treatment protocols, and advance personalized medicine strategies in pediatric ALL.</p></sec></body><back><ack><p><bold>Funding</bold> None.</p><p><bold>Ethical approval</bold> granted by the Ethics Committee of the University Hospital Centre Zagreb (02/21 AG) and by the Ethics Committee of the Faculty of Pharmacy and Biochemistry, University of Zagreb (251-62-03-16-30).</p><p><bold>Declaration of authorship</bold> KD, DB conceived and designed the study; KD, RLT, EB, JK, LJR, RF, MP, GJ, JR, S&#x0010c;, DK, VA, KMT, S&#x00160; acquired the data; KD, RLT, RF, KGK, SR, MS, IF&#x00160;, RZ, MRA, IH, BL, DB analyzed and interpreted the data; KD, DB drafted the manuscript; all authors critically reviewed the manuscript for important intellectual content; all authors approved the version to be submitted; all authors agree to be accountable for all aspects of the work.</p><p><bold>Competing interests</bold> All authors have completed the Unified Competing Interest form at <ext-link xlink:href="http://www.icmje.org/coi_disclosure.pdf" ext-link-type="uri">www.icmje.org/coi_disclosure.pdf</ext-link> (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.</p></ack><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hunger</surname><given-names>SP</given-names></name>
<name><surname>Mullighan</surname><given-names>CG</given-names></name>
</person-group>
<article-title>Acute lymphoblastic leukemia in children.</article-title>
<source>N Engl J Med</source>
<year>2015</year>
<volume>373</volume>
<fpage>1541</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMra1400972</pub-id>
<pub-id pub-id-type="pmid">26465987</pub-id>
</mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="book">Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press;2017.</mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pui</surname><given-names>CH</given-names></name>
<name><surname>Yang</surname><given-names>JJ</given-names></name>
<name><surname>Hunger</surname><given-names>SP</given-names></name>
<name><surname>Pieters</surname><given-names>R</given-names></name>
<name><surname>Schrappe</surname><given-names>M</given-names></name>
<name><surname>Biondi</surname><given-names>A</given-names></name>
<etal/>
</person-group>
<article-title>Childhood acute lymphoblastic leukemia: Progress through collaboration.</article-title>
<source>J Clin Oncol</source>
<year>2015</year>
<volume>33</volume>
<fpage>2938</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1200/JCO.2014.59.1636</pub-id>
<pub-id pub-id-type="pmid">26304874</pub-id>
</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Basso</surname><given-names>G</given-names></name>
<name><surname>Veltroni</surname><given-names>M</given-names></name>
<name><surname>Valsecchi</surname><given-names>MG</given-names></name>
<name><surname>Dworzak</surname><given-names>MN</given-names></name>
<name><surname>Ratei</surname><given-names>R</given-names></name>
<name><surname>Silvestri</surname><given-names>D</given-names></name>
<etal/>
</person-group>
<article-title>Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.</article-title>
<source>J Clin Oncol</source>
<year>2009</year>
<volume>27</volume>
<fpage>5168</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1200/JCO.2008.20.8934</pub-id>
<pub-id pub-id-type="pmid">19805690</pub-id>
</mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bruggemann</surname><given-names>M</given-names></name>
<name><surname>Schrauder</surname><given-names>A</given-names></name>
<name><surname>Raff</surname><given-names>T</given-names></name>
<name><surname>Pfeifer</surname><given-names>H</given-names></name>
<name><surname>Dworzak</surname><given-names>M</given-names></name>
<name><surname>Ottmann</surname><given-names>OG</given-names></name>
<etal/>
</person-group>
<article-title>Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18&#x02013;20 September 2008.</article-title>
<source>Leukemia</source>
<year>2010</year>
<volume>24</volume>
<fpage>521</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1038/leu.2009.268</pub-id>
<pub-id pub-id-type="pmid">20033054</pub-id>
</mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dworzak</surname><given-names>MN</given-names></name>
<name><surname>Gaipa</surname><given-names>G</given-names></name>
<name><surname>Ratei</surname><given-names>R</given-names></name>
<name><surname>Veltroni</surname><given-names>M</given-names></name>
<name><surname>Schumich</surname><given-names>A</given-names></name>
<name><surname>Maglia</surname><given-names>O</given-names></name>
<etal/>
</person-group>
<article-title>Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multi-centric assessment is feasible. Results of the AIEOP BFM-ALL-FCM-MRD Study Group.</article-title>
<source>Cytometry B Clin Cytom</source>
<year>2008</year>
<volume>74</volume>
<fpage>331</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="doi">10.1002/cyto.b.20430</pub-id>
<pub-id pub-id-type="pmid">18548617</pub-id>
</mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Conter</surname><given-names>V</given-names></name>
<name><surname>Bartram</surname><given-names>CR</given-names></name>
<name><surname>Valsecchi</surname><given-names>MG</given-names></name>
<name><surname>Schrauder</surname><given-names>A</given-names></name>
<name><surname>Panzer-Gr&#x000fc;mayer</surname><given-names>R</given-names></name>
<name><surname>M&#x000f6;ricke</surname><given-names>A</given-names></name>
<etal/>
</person-group>
<article-title>Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.</article-title>
<source>Blood</source>
<year>2010</year>
<volume>115</volume>
<fpage>3206</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2009-10-248146</pub-id>
<pub-id pub-id-type="pmid">20154213</pub-id>
</mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fronkova</surname><given-names>E</given-names></name>
<name><surname>Mejstrikova</surname><given-names>E</given-names></name>
<name><surname>Avigad</surname><given-names>S</given-names></name>
<name><surname>Chik</surname><given-names>KW</given-names></name>
<name><surname>Castillo</surname><given-names>L</given-names></name>
<name><surname>Manor</surname><given-names>S</given-names></name>
<etal/>
</person-group>
<article-title>Minimal residual disease (MRD) analysis in the non-MRD based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?</article-title>
<source>Leukemia</source>
<year>2008</year>
<volume>22</volume>
<fpage>989</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="doi">10.1038/leu.2008.22</pub-id>
<pub-id pub-id-type="pmid">18305563</pub-id>
</mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mejstr&#x000ed;kov&#x000e1;</surname><given-names>E</given-names></name>
<name><surname>Fronkov&#x000e1;</surname><given-names>E</given-names></name>
<name><surname>Kalina</surname><given-names>T</given-names></name>
<name><surname>Omelka</surname><given-names>M</given-names></name>
<name><surname>Batinic</surname><given-names>D</given-names></name>
<name><surname>Dubravcic</surname><given-names>K</given-names></name>
<etal/>
</person-group>
<article-title>Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry.</article-title>
<source>Pediatr Blood Cancer</source>
<year>2010</year>
<volume>54</volume>
<fpage>62</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="doi">10.1002/pbc.22261</pub-id>
<pub-id pub-id-type="pmid">19760767</pub-id>
</mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Stary</surname><given-names>J</given-names></name>
<name><surname>Zimmermann</surname><given-names>M</given-names></name>
<name><surname>Campbell</surname><given-names>M</given-names></name>
<name><surname>Castillo</surname><given-names>L</given-names></name>
<name><surname>Dibar</surname><given-names>E</given-names></name>
<name><surname>Donska</surname><given-names>S</given-names></name>
<etal/>
</person-group>
<article-title>Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002.</article-title>
<source>J Clin Oncol</source>
<year>2014</year>
<volume>32</volume>
<fpage>174</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="doi">10.1200/JCO.2013.48.6522</pub-id>
<pub-id pub-id-type="pmid">24344215</pub-id>
</mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Campbell</surname><given-names>M</given-names></name>
<name><surname>Kiss</surname><given-names>C</given-names></name>
<name><surname>Zimmermann</surname><given-names>M</given-names></name>
<name><surname>Riccheri</surname><given-names>C</given-names></name>
<name><surname>Kowalczyk</surname><given-names>J</given-names></name>
<name><surname>Felice</surname><given-names>MS</given-names></name>
<etal/>
</person-group>
<article-title>Childhood acute lymphoblastic leukemia: results of the randomized acute lymphoblastic leukemia intercontinental-Berlin-Frankfurt-M&#x000fc;nster 2009 Trial.</article-title>
<source>J Clin Oncol</source>
<year>2023</year>
<volume>41</volume>
<fpage>3499</fpage>
<lpage>511</lpage>
<pub-id pub-id-type="doi">10.1200/JCO.22.01760</pub-id>
<pub-id pub-id-type="pmid">37141547</pub-id>
</mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Campana</surname><given-names>D</given-names></name>
</person-group>
<article-title>Minimal residual disease in acute lymphoblastic leukemia.</article-title>
<source>Hematology (Am Soc Hematol Educ Program)</source>
<year>2010</year>
<volume>2010</volume>
<fpage>7</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1182/asheducation-2010.1.7</pub-id>
<pub-id pub-id-type="pmid">21239764</pub-id>
</mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Borowitz</surname><given-names>MJ</given-names></name>
<name><surname>Devidas</surname><given-names>M</given-names></name>
<name><surname>Hunger</surname><given-names>SP</given-names></name>
<name><surname>Bowman</surname><given-names>WP</given-names></name>
<name><surname>Carroll</surname><given-names>AJ</given-names></name>
<name><surname>Carroll</surname><given-names>WL</given-names></name>
<etal/>
<collab>Children&#x02019;s Oncology Group</collab>
</person-group>
<article-title>Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factor. A Children&#x02019;s Oncology Group study.</article-title>
<source>Blood</source>
<year>2008</year>
<volume>111</volume>
<fpage>5477</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2008-01-132837</pub-id>
<pub-id pub-id-type="pmid">18388178</pub-id>
</mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Br&#x000fc;ggemann</surname><given-names>M</given-names></name>
<name><surname>Raff</surname><given-names>T</given-names></name>
<name><surname>Kneba</surname><given-names>M</given-names></name>
</person-group>
<article-title>Has MRD monitoring superseded other prognostic factors in adult ALL?</article-title>
<source>Blood</source>
<year>2012</year>
<volume>120</volume>
<fpage>4470</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2012-06-379040</pub-id>
<pub-id pub-id-type="pmid">23033265</pub-id>
</mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>B&#x000e9;n&#x000e9;</surname><given-names>MC</given-names></name>
<name><surname>Castoldi</surname><given-names>G</given-names></name>
<name><surname>Knapp</surname><given-names>W</given-names></name>
<name><surname>Ludwig</surname><given-names>WD</given-names></name>
<name><surname>Matutes</surname><given-names>E</given-names></name>
<name><surname>Orfao</surname><given-names>A</given-names></name>
<etal/>
</person-group>
<article-title>Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL).</article-title>
<source>Leukemia</source>
<year>1995</year>
<volume>9</volume>
<fpage>1783</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">7564526</pub-id>
</mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dworzak</surname><given-names>MN</given-names></name>
<name><surname>Buldini</surname><given-names>B</given-names></name>
<name><surname>Gaipa</surname><given-names>G</given-names></name>
<name><surname>Ratei</surname><given-names>R</given-names></name>
<name><surname>Hrusak</surname><given-names>O</given-names></name>
<name><surname>Luria</surname><given-names>D</given-names></name>
<etal/>
</person-group>
<article-title>International-BFM-FLOW-network. AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia.</article-title>
<source>Cytometry B Clin Cytom</source>
<year>2018</year>
<volume>94</volume>
<fpage>82</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.1002/cyto.b.21518</pub-id>
<pub-id pub-id-type="pmid">28187514</pub-id>
</mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gaipa</surname><given-names>G</given-names></name>
<name><surname>Basso</surname><given-names>G</given-names></name>
<name><surname>Biondi</surname><given-names>A</given-names></name>
<name><surname>Campana</surname><given-names>D</given-names></name>
</person-group>
<article-title>Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.</article-title>
<source>Cytometry B Clin Cytom</source>
<year>2013</year>
<volume>84</volume>
<fpage>359</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="doi">10.1002/cyto.b.21101</pub-id>
<pub-id pub-id-type="pmid">23757107</pub-id>
</mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Karawajew</surname><given-names>L</given-names></name>
<name><surname>Dworzak</surname><given-names>M</given-names></name>
<name><surname>Ratei</surname><given-names>R</given-names></name>
<name><surname>Rhein</surname><given-names>P</given-names></name>
<name><surname>Gaipa</surname><given-names>G</given-names></name>
<name><surname>Buldini</surname><given-names>B</given-names></name>
<etal/>
</person-group>
<article-title>Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.</article-title>
<source>Haematologica</source>
<year>2015</year>
<volume>100</volume>
<fpage>935</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.3324/haematol.2014.116707</pub-id>
<pub-id pub-id-type="pmid">26001791</pub-id>
</mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gleissner</surname><given-names>B</given-names></name>
<name><surname>Goekbuget</surname><given-names>N</given-names></name>
<name><surname>Rieder</surname><given-names>H</given-names></name>
<name><surname>Arnold</surname><given-names>R</given-names></name>
<name><surname>Schwartz</surname><given-names>S</given-names></name>
<name><surname>Diedrich</surname><given-names>H</given-names></name>
<etal/>
</person-group>
<article-title>CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL).</article-title>
<source>Blood</source>
<year>2005</year>
<volume>106</volume>
<fpage>4054</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2005-05-1866</pub-id>
<pub-id pub-id-type="pmid">16123216</pub-id>
</mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Coustan-Smith</surname><given-names>E</given-names></name>
<name><surname>Mullighan</surname><given-names>CG</given-names></name>
<name><surname>Onciu</surname><given-names>M</given-names></name>
<name><surname>Behm</surname><given-names>FG</given-names></name>
<name><surname>Raimondi</surname><given-names>SC</given-names></name>
<name><surname>Pei</surname><given-names>D</given-names></name>
<etal/>
</person-group>
<article-title>Early T-cell precursor leukemia: a subtype of very high-risk acute lymphoblastic leukemia identified in two independent cohorts.</article-title>
<source>Lancet Oncol</source>
<year>2009</year>
<volume>10</volume>
<fpage>147</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.1016/S1470-2045(08)70314-0</pub-id>
<pub-id pub-id-type="pmid">19147408</pub-id>
</mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Conter</surname><given-names>V</given-names></name>
<name><surname>Valsecchi</surname><given-names>MG</given-names></name>
<name><surname>Buldini</surname><given-names>B</given-names></name>
<name><surname>Parasole</surname><given-names>R</given-names></name>
<name><surname>Locatelli</surname><given-names>F</given-names></name>
<name><surname>Colombini</surname><given-names>A</given-names></name>
<etal/>
</person-group>
<article-title>Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centers with AIEOP-BFM protocols: a retrospective analysis.</article-title>
<source>Lancet Haematol</source>
<year>2016</year>
<volume>3</volume>
<fpage>e80</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1016/S2352-3026(15)00254-9</pub-id>
<pub-id pub-id-type="pmid">26853647</pub-id>
</mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rhein</surname><given-names>P</given-names></name>
<name><surname>Mitlohner</surname><given-names>R</given-names></name>
<name><surname>Basso</surname><given-names>G</given-names></name>
<name><surname>Gaipa</surname><given-names>G</given-names></name>
<name><surname>Dworzak</surname><given-names>MN</given-names></name>
<name><surname>Kirschner-Schwabe</surname><given-names>R</given-names></name>
<etal/>
</person-group>
<article-title>CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia.</article-title>
<source>Blood</source>
<year>2010</year>
<volume>115</volume>
<fpage>3763</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2009-10-247585</pub-id>
<pub-id pub-id-type="pmid">20228269</pub-id>
</mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Cario</surname><given-names>G</given-names></name>
<name><surname>Rhein</surname><given-names>P</given-names></name>
<name><surname>Mitl&#x000f6;hner</surname><given-names>R</given-names></name>
<name><surname>Zimmermann</surname><given-names>M</given-names></name>
<name><surname>Bandapalli</surname><given-names>OR</given-names></name>
<name><surname>Romey</surname><given-names>R</given-names></name>
<etal/>
</person-group>
<article-title>High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.</article-title>
<source>Haematologica</source>
<year>2014</year>
<volume>99</volume>
<fpage>103</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.3324/haematol.2013.090225</pub-id>
<pub-id pub-id-type="pmid">23911702</pub-id>
</mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Eidenschink Brodersen</surname><given-names>L</given-names></name>
<name><surname>Alonzo</surname><given-names>TA</given-names></name>
<name><surname>Menssen</surname><given-names>AJ</given-names></name>
<name><surname>Gerbing</surname><given-names>RB</given-names></name>
<name><surname>Pardo</surname><given-names>L</given-names></name>
<name><surname>Voigt</surname><given-names>AP</given-names></name>
<etal/>
</person-group>
<article-title>A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children&#x02019;s Oncology Group.</article-title>
<source>Leukemia</source>
<year>2016</year>
<volume>30</volume>
<fpage>2077</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1038/leu.2016.119</pub-id>
<pub-id pub-id-type="pmid">27133823</pub-id>
</mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>M&#x000f6;ricke</surname><given-names>A</given-names></name>
<name><surname>Zimmermann</surname><given-names>M</given-names></name>
<name><surname>Kunz</surname><given-names>JB</given-names></name>
<name><surname>Kulozik</surname><given-names>AE</given-names></name>
<name><surname>Ludwig</surname><given-names>WD</given-names></name>
<name><surname>Schrappe</surname><given-names>M</given-names></name>
<etal/>
</person-group>
<article-title>Expression of CD56 defines a distinct subgroup in childhood T-ALL with inferior outcome. Results of the ALL-BFM 2000 trial.</article-title>
<source>Br J Haematol</source>
<year>2018</year>
<volume>183</volume>
<fpage>96</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="doi">10.1111/bjh.15503</pub-id>
<pub-id pub-id-type="pmid">30028023</pub-id>
</mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Maurer-Granofszky</surname><given-names>M</given-names></name>
<name><surname>Schumich</surname><given-names>A</given-names></name>
<name><surname>Buldini</surname><given-names>B</given-names></name>
<name><surname>Gaipa</surname><given-names>G</given-names></name>
<name><surname>Kappelmayer</surname><given-names>J</given-names></name>
<name><surname>Mejstrikova</surname><given-names>E</given-names></name>
<etal/>
</person-group>
<article-title>An extensive quality control and quality assurance (QC/QA) program significantly improves inter-laboratory concordance rates of flow-cytometric minimal residual disease assessment in acute lymphoblastic leukemia: An I-BFM-FLOW-Network Report.</article-title>
<source>Cancers (Basel)</source>
<year>2021</year>
<volume>13</volume>
<fpage>6148</fpage>
<pub-id pub-id-type="doi">10.3390/cancers13236148</pub-id>
<pub-id pub-id-type="pmid">34885257</pub-id>
</mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lucio</surname><given-names>P</given-names></name>
<name><surname>Gaipa</surname><given-names>G</given-names></name>
<name><surname>van Lochem</surname><given-names>EG</given-names></name>
<name><surname>van Wering</surname><given-names>ER</given-names></name>
<name><surname>Porwit-MacDonald</surname><given-names>A</given-names></name>
<name><surname>Faria</surname><given-names>T</given-names></name>
<etal/>
</person-group>
<article-title>BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation.</article-title>
<source>Leukemia</source>
<year>2001</year>
<volume>15</volume>
<fpage>1185</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1038/sj.leu.2402150</pub-id>
<pub-id pub-id-type="pmid">11480560</pub-id>
</mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="book">Rooney DE. Human cytogenetics: malignancy and acquired abnormalities. 3rd edition. Oxford University Press; New York: 2001.</mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="book">Shaffer LG, Slovak ML, Campbell LJ, editors. ISCN 2009: An international system for human cytogenetic nomenclature. Basel, Switzerland: S. Karger, 2009.</mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>van Dongen</surname><given-names>JJ</given-names></name>
<name><surname>Macintyre</surname><given-names>EA</given-names></name>
<name><surname>Gabert</surname><given-names>JA</given-names></name>
<name><surname>Delabesse</surname><given-names>E</given-names></name>
<name><surname>Rossi</surname><given-names>V</given-names></name>
<name><surname>Saglio</surname><given-names>G</given-names></name>
<etal/>
</person-group>
<article-title>Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.</article-title>
<source>Leukemia</source>
<year>1999</year>
<volume>13</volume>
<fpage>1901</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1038/sj.leu.2401592</pub-id>
<pub-id pub-id-type="pmid">10602411</pub-id>
</mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Batini&#x00107;</surname><given-names>D</given-names></name>
<name><surname>Borani&#x00107;</surname><given-names>M</given-names></name>
<name><surname>Tiefenbach</surname><given-names>A</given-names></name>
<name><surname>Raji&#x00107;</surname><given-names>L</given-names></name>
<name><surname>Femeni&#x00107;-Kes</surname><given-names>R</given-names></name>
<name><surname>Konja</surname><given-names>J</given-names></name>
</person-group>
<article-title>Subsets of childhood acute lymphoblastic leukaemia in Croatia.</article-title>
<source>Biomed Pharmacother</source>
<year>1988</year>
<volume>42</volume>
<fpage>133</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="pmid">3167167</pub-id>
</mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chiaretti</surname><given-names>S</given-names></name>
<name><surname>Vitale</surname><given-names>A</given-names></name>
<name><surname>Cazzaniga</surname><given-names>G</given-names></name>
<name><surname>Orlando</surname><given-names>SM</given-names></name>
<name><surname>Silvestri</surname><given-names>D</given-names></name>
<name><surname>Fazi</surname><given-names>P</given-names></name>
<etal/>
</person-group>
<article-title>Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts.</article-title>
<source>Haematologica</source>
<year>2013</year>
<volume>98</volume>
<fpage>1702</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.3324/haematol.2012.080432</pub-id>
<pub-id pub-id-type="pmid">23716539</pub-id>
</mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hrus&#x000e1;k</surname><given-names>O</given-names></name>
<name><surname>Porwit-MacDonald</surname><given-names>A</given-names></name>
</person-group>
<article-title>Antigen expression patterns reflecting genotype of acute leukemias.</article-title>
<source>Leukemia</source>
<year>2002</year>
<volume>16</volume>
<fpage>1233</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="doi">10.1038/sj.leu.2402504</pub-id>
<pub-id pub-id-type="pmid">12094248</pub-id>
</mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Forestier</surname><given-names>E</given-names></name>
<name><surname>Johansson</surname><given-names>B</given-names></name>
<name><surname>Borgstr&#x000f6;m</surname><given-names>G</given-names></name>
<name><surname>Kerndrup</surname><given-names>G</given-names></name>
<name><surname>Johannsson</surname><given-names>J</given-names></name>
<name><surname>Heim</surname><given-names>S</given-names></name>
</person-group>
<article-title>Cytogenetic findings in a population-based series of 787 childhood acute lymphoblastic leukemias from the Nordic countries. The NOPHO Leukemia Cytogenetic Study Group.</article-title>
<source>Eur J Haematol</source>
<year>2000</year>
<volume>64</volume>
<fpage>194</fpage>
<lpage>200</lpage>
<pub-id pub-id-type="doi">10.1034/j.1600-0609.2000.90103.x</pub-id>
<pub-id pub-id-type="pmid">10997886</pub-id>
</mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Harrison</surname><given-names>CJ</given-names></name>
<name><surname>Moorman</surname><given-names>AV</given-names></name>
<name><surname>Barber</surname><given-names>KE</given-names></name>
<name><surname>Broadfield</surname><given-names>ZJ</given-names></name>
<name><surname>Cheung</surname><given-names>KL</given-names></name>
<name><surname>Harris</surname><given-names>RL</given-names></name>
<etal/>
</person-group>
<article-title>Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study.</article-title>
<source>Br J Haematol</source>
<year>2005</year>
<volume>129</volume>
<fpage>520</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2141.2005.05497.x</pub-id>
<pub-id pub-id-type="pmid">15877734</pub-id>
</mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Harrison</surname><given-names>CJ</given-names></name>
<name><surname>Haas</surname><given-names>O</given-names></name>
<name><surname>Harbott</surname><given-names>J</given-names></name>
<name><surname>Biondi</surname><given-names>A</given-names></name>
<name><surname>Stanulla</surname><given-names>M</given-names></name>
<name><surname>Trka</surname><given-names>J</given-names></name>
<etal/>
</person-group>
<article-title>Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfurt-M&#x000fc;nster study group.</article-title>
<source>Br J Haematol</source>
<year>2010</year>
<volume>151</volume>
<fpage>132</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2141.2010.08314.x</pub-id>
<pub-id pub-id-type="pmid">20701601</pub-id>
</mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Moorman</surname><given-names>AV</given-names></name>
<name><surname>Ensor</surname><given-names>HM</given-names></name>
<name><surname>Richards</surname><given-names>SM</given-names></name>
<name><surname>Chilton</surname><given-names>L</given-names></name>
<name><surname>Schwab</surname><given-names>C</given-names></name>
<name><surname>Kinsey</surname><given-names>SE</given-names></name>
<etal/>
</person-group>
<article-title>Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial.</article-title>
<source>Lancet Oncol</source>
<year>2010</year>
<volume>11</volume>
<fpage>429</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1016/S1470-2045(10)70066-8</pub-id>
<pub-id pub-id-type="pmid">20409752</pub-id>
</mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Inaba</surname><given-names>H</given-names></name>
<name><surname>Pui</surname><given-names>CH</given-names></name>
</person-group>
<article-title>Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia.</article-title>
<source>J Clin Med</source>
<year>2021</year>
<volume>10</volume>
<fpage>1926</fpage>
<pub-id pub-id-type="doi">10.3390/jcm10091926</pub-id>
<pub-id pub-id-type="pmid">33946897</pub-id>
</mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hunger</surname><given-names>SP</given-names></name>
<name><surname>Lu</surname><given-names>X</given-names></name>
<name><surname>Devidas</surname><given-names>M</given-names></name>
<name><surname>Camitta</surname><given-names>BM</given-names></name>
<name><surname>Gaynon</surname><given-names>PS</given-names></name>
<name><surname>Winick</surname><given-names>NJ</given-names></name>
<etal/>
</person-group>
<article-title>Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children&#x02019;s oncology group.</article-title>
<source>J Clin Oncol</source>
<year>2012</year>
<volume>30</volume>
<fpage>1663</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1200/JCO.2011.37.8018</pub-id>
<pub-id pub-id-type="pmid">22412151</pub-id>
</mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kowalczyk</surname><given-names>JR</given-names></name>
<name><surname>Zawitkowska</surname><given-names>J</given-names></name>
<name><surname>Lejman</surname><given-names>M</given-names></name>
<name><surname>Drabko</surname><given-names>K</given-names></name>
<name><surname>Samardakiewicz</surname><given-names>M</given-names></name>
<name><surname>Matysiak</surname><given-names>M</given-names></name>
<etal/>
</person-group>
<article-title>Long-term treatment results of Polish pediatric and adolescent patients enrolled in the ALL IC-BFM 2002 trial.</article-title>
<source>Am J Hematol</source>
<year>2019</year>
<volume>94</volume>
<fpage>E307</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1002/ajh.25619</pub-id>
<pub-id pub-id-type="pmid">31432528</pub-id>
</mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Verbeek</surname><given-names>MWC</given-names></name>
<name><surname>van der Velden</surname><given-names>VHJ</given-names></name>
</person-group>
<article-title>The evolving landscape of flowcytometric minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia.</article-title>
<source>Int J Mol Sci</source>
<year>2024</year>
<volume>25</volume>
<fpage>4881</fpage>
<pub-id pub-id-type="doi">10.3390/ijms25094881</pub-id>
<pub-id pub-id-type="pmid">38732101</pub-id>
</mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Vitale</surname><given-names>A</given-names></name>
<name><surname>Guarini</surname><given-names>A</given-names></name>
<name><surname>Ariola</surname><given-names>C</given-names></name>
<name><surname>Meloni</surname><given-names>G</given-names></name>
<name><surname>Perbellini</surname><given-names>O</given-names></name>
<name><surname>Pizzuti</surname><given-names>M</given-names></name>
<etal/>
</person-group>
<article-title>Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial.</article-title>
<source>Haematologica</source>
<year>2007</year>
<volume>92</volume>
<fpage>342</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.3324/haematol.10385</pub-id>
<pub-id pub-id-type="pmid">17339183</pub-id>
</mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Craddock</surname><given-names>KJ</given-names></name>
<name><surname>Chen</surname><given-names>Y</given-names></name>
<name><surname>Brandwein</surname><given-names>JM</given-names></name>
<name><surname>Chang</surname><given-names>H</given-names></name>
</person-group>
<article-title>CD13 expression is an independent adverse prognostic factor in adults with Philadelphia chromosome negative B cell acute lymphoblastic leukemia.</article-title>
<source>Leuk Res</source>
<year>2013</year>
<volume>37</volume>
<fpage>759</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="doi">10.1016/j.leukres.2013.04.006</pub-id>
<pub-id pub-id-type="pmid">23643324</pub-id>
</mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dalal</surname><given-names>BI</given-names></name>
<name><surname>Al Mugairi</surname><given-names>A</given-names></name>
<name><surname>Pi</surname><given-names>S</given-names></name>
<name><surname>Lee</surname><given-names>SY</given-names></name>
<name><surname>Khare</surname><given-names>NS</given-names></name>
<name><surname>Pal</surname><given-names>J</given-names></name>
<etal/>
</person-group>
<article-title>Aberrant expression of CD13 identifies a subgroup of standard-risk adult acute lymphoblastic leukemia with inferior survival.</article-title>
<source>Clin Lymphoma Myeloma Leuk</source>
<year>2014</year>
<volume>14</volume>
<fpage>239</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1016/j.clml.2013.10.003</pub-id>
<pub-id pub-id-type="pmid">24411984</pub-id>
</mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Liao</surname><given-names>H</given-names></name>
<name><surname>Lai</surname><given-names>H</given-names></name>
<name><surname>Chen</surname><given-names>J</given-names></name>
<name><surname>Shuai</surname><given-names>X</given-names></name>
<name><surname>Zhang</surname><given-names>X</given-names></name>
<name><surname>Yang</surname><given-names>Y</given-names></name>
<etal/>
</person-group>
<article-title>Prognostic value of cross-lineage expression of the myeloid-associated antigens CD13 and CD33 in adult B-lymphoblastic leukemia: A large real-world study of 1005 patients.</article-title>
<source>Cancer Med</source>
<year>2023</year>
<volume>12</volume>
<fpage>9615</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1002/cam4.5739</pub-id>
<pub-id pub-id-type="pmid">36951610</pub-id>
</mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Borowitz</surname><given-names>MJ</given-names></name>
<name><surname>Shuster</surname><given-names>J</given-names></name>
<name><surname>Carroll</surname><given-names>AJ</given-names></name>
<name><surname>Nash</surname><given-names>M</given-names></name>
<name><surname>Look</surname><given-names>AT</given-names></name>
<name><surname>Camitta</surname><given-names>B</given-names></name>
<etal/>
</person-group>
<article-title>Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study.</article-title>
<source>Blood</source>
<year>1997</year>
<volume>89</volume>
<fpage>3960</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1182/blood.V89.11.3960</pub-id>
<pub-id pub-id-type="pmid">9166833</pub-id>
</mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Thomas</surname><given-names>DA</given-names></name>
<name><surname>O&#x02019;Brien</surname><given-names>S</given-names></name>
<name><surname>Jorgensen</surname><given-names>JL</given-names></name>
<name><surname>Cortes</surname><given-names>J</given-names></name>
<name><surname>Faderl</surname><given-names>S</given-names></name>
<name><surname>Garcia-Manero</surname><given-names>G</given-names></name>
<etal/>
</person-group>
<article-title>Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.</article-title>
<source>Blood</source>
<year>2009</year>
<volume>113</volume>
<fpage>6330</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2008-04-151860</pub-id>
<pub-id pub-id-type="pmid">18703706</pub-id>
</mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jeha</surname><given-names>S</given-names></name>
<name><surname>Behm</surname><given-names>F</given-names></name>
<name><surname>Pei</surname><given-names>D</given-names></name>
<name><surname>Sandlund</surname><given-names>JT</given-names></name>
<name><surname>Ribeiro</surname><given-names>RC</given-names></name>
<name><surname>Razzouk</surname><given-names>BI</given-names></name>
<etal/>
</person-group>
<article-title>Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia.</article-title>
<source>Blood</source>
<year>2006</year>
<volume>108</volume>
<fpage>3302</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2006-04-016709</pub-id>
<pub-id pub-id-type="pmid">16896151</pub-id>
</mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dworzak</surname><given-names>MN</given-names></name>
<name><surname>Schumich</surname><given-names>A</given-names></name>
<name><surname>Printz</surname><given-names>D</given-names></name>
<name><surname>P&#x000f6;tschger</surname><given-names>U</given-names></name>
<name><surname>Husak</surname><given-names>Z</given-names></name>
<name><surname>Attarbaschi</surname><given-names>A</given-names></name>
<etal/>
</person-group>
<article-title>CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.</article-title>
<source>Blood</source>
<year>2008</year>
<volume>112</volume>
<fpage>3982</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2008-06-164129</pub-id>
<pub-id pub-id-type="pmid">18780832</pub-id>
</mixed-citation></ref><ref id="R50"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mannelli</surname><given-names>F</given-names></name>
<name><surname>Gianfaldoni</surname><given-names>G</given-names></name>
<name><surname>Intermesoli</surname><given-names>T</given-names></name>
<name><surname>Cattaneo</surname><given-names>C</given-names></name>
<name><surname>Borlenghi</surname><given-names>E</given-names></name>
<name><surname>Cortelazzo</surname><given-names>S</given-names></name>
<etal/>
</person-group>
<article-title>CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease.</article-title>
<source>Haematologica</source>
<year>2012</year>
<volume>97</volume>
<fpage>568</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="doi">10.3324/haematol.2011.054064</pub-id>
<pub-id pub-id-type="pmid">22058217</pub-id>
</mixed-citation></ref><ref id="R51"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Borowitz</surname><given-names>MJ</given-names></name>
<name><surname>Shuster</surname><given-names>JJ</given-names></name>
<name><surname>Civin</surname><given-names>CI</given-names></name>
<name><surname>Carroll</surname><given-names>AJ</given-names></name>
<name><surname>Look</surname><given-names>AT</given-names></name>
<name><surname>Behm</surname><given-names>FG</given-names></name>
<etal/>
</person-group>
<article-title>Prognostic significance of CD34 expression in childhood B-precursor acute lymphocytic leukemia: a Pediatric Oncology Group study.</article-title>
<source>J Clin Oncol</source>
<year>1990</year>
<volume>8</volume>
<fpage>1389</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="doi">10.1200/JCO.1990.8.8.1389</pub-id>
<pub-id pub-id-type="pmid">1696310</pub-id>
</mixed-citation></ref><ref id="R52"><label>52</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pui</surname><given-names>CH</given-names></name>
<name><surname>Hancock</surname><given-names>ML</given-names></name>
<name><surname>Head</surname><given-names>DR</given-names></name>
<name><surname>Rivera</surname><given-names>GK</given-names></name>
<name><surname>Look</surname><given-names>AT</given-names></name>
<name><surname>Sandlund</surname><given-names>JT</given-names></name>
<etal/>
</person-group>
<article-title>Clinical significance of CD34 expression in childhood acute lymphoblastic leukemia.</article-title>
<source>Blood</source>
<year>1993</year>
<volume>82</volume>
<fpage>889</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1182/blood.V82.3.889.889</pub-id>
<pub-id pub-id-type="pmid">7687897</pub-id>
</mixed-citation></ref><ref id="R53"><label>53</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nakamura</surname><given-names>A</given-names></name>
<name><surname>Tsurusawa</surname><given-names>M</given-names></name>
<name><surname>Kato</surname><given-names>A</given-names></name>
<name><surname>Taga</surname><given-names>T</given-names></name>
<name><surname>Hatae</surname><given-names>Y</given-names></name>
<name><surname>Miyake</surname><given-names>M</given-names></name>
<etal/>
<collab>Children&#x02019;s Cancer and Leukemia Study Group</collab>
</person-group>
<article-title>Prognostic impact of CD45 antigen expression in high-risk, childhood B-cell precursor acute lymphoblastic leukemia.</article-title>
<source>Leuk Lymphoma</source>
<year>2001</year>
<volume>42</volume>
<fpage>393</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.3109/10428190109064596</pub-id>
<pub-id pub-id-type="pmid">11699404</pub-id>
</mixed-citation></ref><ref id="R54"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Modvig</surname><given-names>S</given-names></name>
<name><surname>Wernersson</surname><given-names>R</given-names></name>
<name><surname>&#x000d8;bro</surname><given-names>NF</given-names></name>
<name><surname>Olsen</surname><given-names>LR</given-names></name>
<name><surname>Christensen</surname><given-names>C</given-names></name>
<name><surname>Rosth&#x000f8;j</surname><given-names>S</given-names></name>
<etal/>
</person-group>
<article-title>High CD34 surface expression in BCP-ALL predicts poor induction therapy response and is associated with altered expression of genes related to cell migration and adhesion.</article-title>
<source>Mol Oncol</source>
<year>2022</year>
<volume>16</volume>
<fpage>2015</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1002/1878-0261.13207</pub-id>
<pub-id pub-id-type="pmid">35271751</pub-id>
</mixed-citation></ref><ref id="R55"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Saxena</surname><given-names>A</given-names></name>
<name><surname>Rai</surname><given-names>A</given-names></name>
<name><surname>Raina</surname><given-names>V</given-names></name>
<name><surname>Seth</surname><given-names>T</given-names></name>
<name><surname>Mitra</surname><given-names>DK</given-names></name>
</person-group>
<article-title>Expression of CD13/aminopeptidase N in precursor B-cell leukemia: role in growth regulation of B cells.</article-title>
<source>Cancer Immunol Immunother</source>
<year>2010</year>
<volume>59</volume>
<fpage>125</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1007/s00262-009-0731-6</pub-id>
<pub-id pub-id-type="pmid">19562339</pub-id>
</mixed-citation></ref><ref id="R56"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Taussig</surname><given-names>DC</given-names></name>
<name><surname>Pearce</surname><given-names>DJ</given-names></name>
<name><surname>Simpson</surname><given-names>C</given-names></name>
<name><surname>Rohatiner</surname><given-names>AZ</given-names></name>
<name><surname>Lister</surname><given-names>TA</given-names></name>
<name><surname>Kelly</surname><given-names>G</given-names></name>
<etal/>
</person-group>
<article-title>Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia.</article-title>
<source>Blood</source>
<year>2005</year>
<volume>106</volume>
<fpage>4086</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2005-03-1072</pub-id>
<pub-id pub-id-type="pmid">16131573</pub-id>
</mixed-citation></ref><ref id="R57"><label>57</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>W</given-names></name>
<name><surname>Blank</surname><given-names>A</given-names></name>
<name><surname>Kremenetskaia</surname><given-names>I</given-names></name>
<name><surname>Nitzsche</surname><given-names>A</given-names></name>
<name><surname>Acker</surname><given-names>G</given-names></name>
<name><surname>Vajkoczy</surname><given-names>P</given-names></name>
<etal/>
</person-group>
<article-title>CD13 expression affects glioma patient survival and influences key functions of human glioblastoma cell lines in vitro.</article-title>
<source>BMC Cancer</source>
<year>2024</year>
<volume>24</volume>
<fpage>369</fpage>
<pub-id pub-id-type="doi">10.1186/s12885-024-12113-z</pub-id>
<pub-id pub-id-type="pmid">38519889</pub-id>
</mixed-citation></ref><ref id="R58"><label>58</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Borowitz</surname><given-names>MJ</given-names></name>
<name><surname>Rubnitz</surname><given-names>J</given-names></name>
<name><surname>Nash</surname><given-names>M</given-names></name>
<name><surname>Pullen</surname><given-names>DJ</given-names></name>
<name><surname>Camitta</surname><given-names>B</given-names></name>
</person-group>
<article-title>Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: a Pediatric Oncology Group study.</article-title>
<source>Leukemia</source>
<year>1998</year>
<volume>12</volume>
<fpage>1764</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="doi">10.1038/sj.leu.2401177</pub-id>
<pub-id pub-id-type="pmid">9823952</pub-id>
</mixed-citation></ref><ref id="R59"><label>59</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tabernero</surname><given-names>MD</given-names></name>
<name><surname>Bortoluci</surname><given-names>AM</given-names></name>
<name><surname>Alaejos</surname><given-names>I</given-names></name>
<name><surname>L&#x000f3;pez-Berges</surname><given-names>MC</given-names></name>
<name><surname>Rasillo</surname><given-names>A</given-names></name>
<name><surname>Garc&#x000ed;a-Sanz</surname><given-names>R</given-names></name>
<etal/>
</person-group>
<article-title>Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expression.</article-title>
<source>Leukemia</source>
<year>2001</year>
<volume>15</volume>
<fpage>406</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1038/sj.leu.2402060</pub-id>
<pub-id pub-id-type="pmid">11237064</pub-id>
</mixed-citation></ref><ref id="R60"><label>60</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jaso</surname><given-names>J</given-names></name>
<name><surname>Thomas</surname><given-names>DA</given-names></name>
<name><surname>Cunningham</surname><given-names>K</given-names></name>
<name><surname>Jorgensen</surname><given-names>JL</given-names></name>
<name><surname>Kantarjian</surname><given-names>HM</given-names></name>
<name><surname>Medeiros</surname><given-names>LJ</given-names></name>
<etal/>
</person-group>
<article-title>Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors.</article-title>
<source>Cancer</source>
<year>2011</year>
<volume>117</volume>
<fpage>4009</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1002/cncr.25978</pub-id>
<pub-id pub-id-type="pmid">21365622</pub-id>
</mixed-citation></ref><ref id="R61"><label>61</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sobol-Milejska</surname><given-names>G</given-names></name>
<name><surname>Mizia-Malarz</surname><given-names>A</given-names></name>
<name><surname>Wos</surname><given-names>H</given-names></name>
</person-group>
<article-title>Expression of myeloid antigens on lymphoblast surface in childhood acute lymphoblastic leukemia at diagnosis and its effect on early response to treatment: a preliminary report.</article-title>
<source>Int J Hematol</source>
<year>2013</year>
<volume>98</volume>
<fpage>331</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1007/s12185-013-1397-6</pub-id>
<pub-id pub-id-type="pmid">23881645</pub-id>
</mixed-citation></ref></ref-list><sec sec-type="supplementary-material"><title>Additional Material</title><supplementary-material id="S1" position="float" content-type="local-data"><caption><title>Supplemental Figure 1</title></caption><media xlink:href="CroatMedJ_66_s001.pdf" id="d67e6392" position="anchor"/></supplementary-material><supplementary-material id="S2" position="float" content-type="local-data"><caption><title>Supplemental Figure 2</title></caption><media xlink:href="CroatMedJ_66_s002.pdf" id="d67e6396" position="anchor"/></supplementary-material><supplementary-material id="S3" position="float" content-type="local-data"><caption><title>Supplemental Figure 3</title></caption><media xlink:href="CroatMedJ_66_s003.pdf" id="d67e6400" position="anchor"/></supplementary-material><supplementary-material id="S4" position="float" content-type="local-data"><caption><title>Supplemental Figure 4</title></caption><media xlink:href="CroatMedJ_66_s004.pdf" id="d67e6404" position="anchor"/></supplementary-material><supplementary-material id="S5" position="float" content-type="local-data"><caption><title>Supplemental Figure 5</title></caption><media xlink:href="CroatMedJ_66_s005.pdf" id="d67e6408" position="anchor"/></supplementary-material><supplementary-material id="S6" position="float" content-type="local-data"><caption><title>Supplemental Methods</title></caption><media xlink:href="CroatMedJ_66_s006.pdf" id="d67e6412" position="anchor"/></supplementary-material><supplementary-material id="S7" position="float" content-type="local-data"><caption><title>Supplemental Table 1</title></caption><media xlink:href="CroatMedJ_66_s007.pdf" id="d67e6416" position="anchor"/></supplementary-material><supplementary-material id="S8" position="float" content-type="local-data"><caption><title>Supplemental Table 2</title></caption><media xlink:href="CroatMedJ_66_s008.pdf" id="d67e6420" position="anchor"/></supplementary-material><supplementary-material id="S9" position="float" content-type="local-data"><caption><title>Supplemental Table 3</title></caption><media xlink:href="CroatMedJ_66_s009.pdf" id="d67e6424" position="anchor"/></supplementary-material><supplementary-material id="S10" position="float" content-type="local-data"><caption><title>Supplemental Table 4</title></caption><media xlink:href="CroatMedJ_66_s010.pdf" id="d67e6428" position="anchor"/></supplementary-material><supplementary-material id="S11" position="float" content-type="local-data"><caption><title>Supplemental Table 5</title></caption><media xlink:href="CroatMedJ_66_s011.pdf" id="d67e6433" position="anchor"/></supplementary-material><supplementary-material id="S12" position="float" content-type="local-data"><caption><title>Supplemental Table 6</title></caption><media xlink:href="CroatMedJ_66_s012.pdf" id="d67e6437" position="anchor"/></supplementary-material><supplementary-material id="S13" position="float" content-type="local-data"><caption><title>Supplemental Table 7</title></caption><media xlink:href="CroatMedJ_66_s013.pdf" id="d67e6441" position="anchor"/></supplementary-material></sec></back></article>